CN1351080A - Human protein with cancer call growth suppressing function and its coding sequence - Google Patents

Abstract

A novel human protein with cancer suppressing function, the polynucleotide for coding it, the process for preparing said polypeptide by recombination, the application of the said polypeptide in treating diseases such as cancer, etc, the antagon of said polypeptide and its medical action, and the application of said polynucleotide are disclosed.

Description

New people's albumen and encoding sequence thereof with anticancer growth function

The invention belongs to biological technical field, specifically, the present invention relates to the proteic polynucleotide of people that new coding has cancer suppressing function, and the polypeptide of this polynucleotide encoding.The invention still further relates to the purposes and the preparation of these polynucleotide and polypeptide.

The research of people's gene group is international focus at present, removes human chromosome DNA large scale sequencing, outside the method for expressed sequence order-checking (EST), also lacks the screening that begins from function and has the high-throughout method of functional gene.

Cancer is one of principal disease of harm humans health.In order to treat effectively and prophylaxis of tumours, people more and more pay close attention to genetic treatment of tumor at present.Therefore, this area presses for people's albumen and the agonist/inhibitor thereof that development research has cancer suppressing function.

The purpose of this invention is to provide the new people's protein polypeptide of a class with cancer suppressing function with and fragment, analogue and derivative.

Another object of the present invention provides the polynucleotide of these polypeptide of coding.

Another object of the present invention provides the method for these polypeptide of production and the purposes of this polypeptide and encoding sequence.

In a first aspect of the present invention, novel isolated protein polypeptide with cancer suppressing function is provided, and it comprises the polypeptide of the aminoacid sequence with the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ IDNO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29; Or its conservative property variation polypeptide or its active fragments or its reactive derivative.

Preferably, this polypeptide is the polypeptide with aminoacid sequence of the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ IDNO:23, SEQ ID NO:26, SEQ ID NO:29.

In a second aspect of the present invention, a kind of isolating polynucleotide are provided, it comprises a nucleotide sequence, and this nucleotide sequence is shown at least 85% homogeny with a kind of nucleotides sequence that is selected from down group: the polynucleotide of the above-mentioned protein polypeptide with cancer suppressing function of (a) encoding; (b) with polynucleotide (a) complementary polynucleotide.Preferably, the polypeptide of this polynucleotide encoding has the aminoacid sequence of the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ IDNO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29.More preferably, the sequence of these polynucleotide is selected from down group: coding region sequence or the full length sequence of SEQ ID NO:3, SEQ ID NO:6, SEQID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30.

In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.

In a fourth aspect of the present invention, the preparation method who prepares the polypeptide of the protein-active with cancer suppressing function is provided, this method comprises: (a) have under the proteic condition of cancer suppressing function suitable the expression, cultivate the above-mentioned host cell that is transformed or transduce; (b) from culture, isolate the polypeptide of protein-active with cancer suppressing function.

In a fifth aspect of the present invention, provide and above-mentioned protein polypeptide specificity bonded antibody with cancer suppressing function.The nucleic acid molecule that can be used for detecting also is provided, and it contains, and continuous 10 Nucleotide are to full length nucleotide in the above-mentioned polynucleotide, and preferably it contains the about 10-800 of a successive Nucleotide.

In a sixth aspect of the present invention, a kind of pharmaceutical composition is provided, it contains the protein polypeptide and the pharmaceutically acceptable carrier with cancer suppressing function of the present invention of safe and effective amount.These pharmaceutical compositions can be treated illnesss such as cancer and cellular abnormality propagation.

Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.

The present invention adopts large-scale cDNA clone transfection cancer cells, has on the basis of cancer suppressing action in acquisition, proves new gene through order-checking, further obtains full length cDNA clone.DNA transfection evidence, the albumen with cancer suppressing function of the present invention has the effect that suppresses clone's formation to cancer cells (liver cancer cell), and its inhibiting rate is more than 50% or 50%.

As used herein, " isolating " is meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.

As used herein, " isolating albumen or polypeptide with cancer suppressing function " is meant that the protein polypeptide with cancer suppressing function is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can have the albumen of cancer suppressing function with the purified technology of protein purifying of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.Purity with protein polypeptide of cancer suppressing function can be used amino acid sequence analysis.

Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.

The present invention also comprises the proteic fragment of the people with cancer suppressing function, derivative and analogue.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep natural identical biological function or the active polypeptide of people's albumen with cancer suppressing function of the present invention basically.Polypeptide fragment of the present invention, derivative or analogue can be that (i) has one or more conservative or substituted polypeptide of non-conservation amino-acid residue (preferred conservative amino acid residue), and the amino-acid residue of such replacement can be also can not encoded by genetic code, or (ii) in one or more amino-acid residues, has a polypeptide of substituted radical, or (iii) mature polypeptide and another compound (such as the compound that prolongs the polypeptide transformation period, polyoxyethylene glycol for example) merge formed polypeptide, or (iv) additional aminoacid sequence is fused to this peptide sequence and the polypeptide that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying).According to the instruction of this paper, these fragments, derivative and analogue belong to the known scope of those skilled in the art.

Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.Be example with PP4491 albumen (in this application, its clone numbering is adopted in proteinic name), the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:3 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that in the present invention coding has the protein of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ IDNO:3.Be example with PP5644 albumen (in this application, its clone numbering is adopted in proteinic name), the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:6 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that in the present invention coding has the protein of SEQ ID NO:5, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:6.Have the albumen of cancer suppressing function for other, can the rest may be inferred.Have the albumen of cancer suppressing function for other, can the rest may be inferred.

The polynucleotide of encoding mature polypeptide comprise: the encoding sequence of an encoding mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.

Term " polynucleotide of coded polypeptide " can be the polynucleotide that comprise this polypeptide of encoding, and also can be the polynucleotide that also comprise additional code and/or non-coding sequence.

The invention still further relates to the varient of above-mentioned polynucleotide, its coding has the polypeptide of identical aminoacid sequence or fragment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.

The invention still further relates to and above-mentioned sequence hybridization and two sequences between have at least 50%, preferably at least 70%, the polynucleotide of at least 80% homogeny more preferably.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time is added with denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function (is example with PP4491 albumen) and activity with the mature polypeptide shown in the SEQ IDNO:2.

The invention still further relates to nucleic acid fragment with above-mentioned sequence hybridization.As used herein, the length of " nucleic acid fragment " contains 15 Nucleotide at least, better is at least 30 Nucleotide, is more preferably at least 50 Nucleotide, preferably more than at least 100 Nucleotide.The amplification technique (as PCR) that nucleic acid fragment can be used for nucleic acid has the proteic polynucleotide of cancer suppressing function to determine and/or to separate to encode.

Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.

Dna sequence dna of the present invention can obtain with several method.For example, with hybridization technique DNA isolation well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homology nucleotide sequence and 2) antibody screening of expression library to be to detect the dna fragmentation of the clone with common structure feature.

The proteic specific DNA fragment sequence that coding has cancer suppressing function produces also and can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of required polypeptide.

In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.When the whole aminoacid sequence of the polypeptide product of needs was known, the direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.When if required amino acid whose whole sequence is not known, the direct chemical of dna sequence dna is synthetic to be impossible, and the method for selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.

Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) function of marker gene occurs or forfeiture; (3) mensuration has the level of the proteic transcript of cancer suppressing function; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.

In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 15 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, the length of probe within 2kb, preferably is within the 1kb usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene DNA sequence information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.

In (4) kind method, detect the protein product of protein gene expression and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc. with cancer suppressing function.

Use method (Saiki, the et al.Science 1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to obtain the cDNA of total length from the library, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.

The gene of the present invention that obtains as mentioned above, perhaps the available ordinary method of mensuration of the nucleotide sequence of various dna fragmentations etc. such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467).This class nucleotide sequencing is available commercial sequencing kit etc. also.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.

The present invention also relates to comprise the carrier of polynucleotide of the present invention, and the host cell that produces through genetically engineered with carrier of the present invention or albumen coded sequence with cancer suppressing function, and the method that produces polypeptide of the present invention through recombinant technology.

Recombinant DNA technology (Science, 1984 by routine; 224:1431), can utilize polymerized nucleoside acid sequence of the present invention to can be used to express or produce the protein polypeptide with cancer suppressing function of reorganization.In general following steps are arranged:

(1). have the proteic polynucleotide of people (or varient) of cancer suppressing function with coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;

(2). the host cell of in suitable medium, cultivating;

(3). separation, protein purification from substratum or cell.

Among the present invention, the people's albumen polynucleotide sequence with cancer suppressing function can be inserted in the recombinant expression vector.Term " recombinant expression vector " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carriers.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on T7 of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier can be used.A key character of expression vector is to contain replication orgin, promotor, marker gene and translation controlling elements usually.

Method well-known to those having ordinary skill in the art can be used to make up and contains people's encoding histone dna sequence dna with cancer suppressing function and suitable transcribing/the translate expression vector of control signal.These methods comprise (Sambroook, et al.Molecular Cloning, a Laboratory Manual, coldSpring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; Lambda particles phage P _LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in protokaryon or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site and the transcription terminator that translation initiation is used.

In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance.

Comprise the carrier of above-mentioned suitable dna sequence dna and suitable promotor or control sequence, can be used to transform appropriate host cell, so that it can marking protein.

Host cell can be a prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; The bacterial cell of Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; The insect cell of fruit bat S2 or Sf9; The zooblast of CHO, COS or Bowes melanoma cells etc.

When polynucleotide of the present invention are expressed in higher eucaryotic cells, be enhanced if will make to transcribe when in carrier, inserting enhancer sequence.Enhanser is the cis acting factor of DNA, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.

Persons skilled in the art all know how to select appropriate carriers, promotor, enhanser and host cell.

Can carry out with routine techniques well known to those skilled in the art with the recombinant DNA transformed host cell.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results ₂Method is handled, and used step is well-known in this area.Alternative is to use MgCl ₂If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, conventional mechanical method such as microinjection, electroporation, liposome packing etc.

The transformant that obtains can be cultivated with ordinary method, expresses the polypeptide of coded by said gene of the present invention.According to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.

Recombinant polypeptide in the above methods can wrap by in cell, extracellular or on cytolemma, express or be secreted into the extracellular.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.The example of these methods includes, but are not limited to: conventional renaturation handles, with protein precipitant handle (salt analysis method), centrifugal, the broken bacterium of infiltration, superly handle, the combination of super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.

The people's albumen or the polypeptide with cancer suppressing function of reorganization are of use in many ways.These purposes include, but is not limited to: directly have the disease due to the low or forfeiture of the protein function of cancer suppressing function as pharmacological agent and be used to screen and promote or antagonism has antibody, polypeptide or other part of the protein function of cancer suppressing function.For example, antibody can be used for activating or suppressing to have the proteic function of people of cancer suppressing function.The people's protein screening peptide library that has a cancer suppressing function with the reorganization of expressing can be used for seeking the peptide molecule that can suppress or stimulate the people's protein function with cancer suppressing function of therapeutic value.

The present invention also provides screening of medicaments to improve (agonist) or check the method that (antagonist) has the proteic medicament of people of cancer suppressing function to identify.Agonist improves the biological function such as stimulate cellular proliferation of the people's albumen with cancer suppressing function, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can be in the presence of medicine, the proteic film preparation of people that mammalian cell or expression is had cancer suppressing function is cultivated with the people's albumen with cancer suppressing function of mark.Measure the medicine raising then or check this interactional ability.

The proteic antagonist of people with cancer suppressing function comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The proteic antagonist of people with cancer suppressing function can and be eliminated its function with the people's protein binding with cancer suppressing function, or suppresses to have the proteic generation of people of cancer suppressing function, or combines with the avtive spot of polypeptide and to make polypeptide can not bring into play biological function.The proteic antagonist of people with cancer suppressing function can be used for therepic use.

In screening during as the compound of antagonist, the albumen that can have a cancer suppressing function adds during bioanalysis measures, and determines by measuring albumen and the interaction between its acceptor that compounds affect has cancer suppressing function whether compound is antagonist.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.

Polypeptide of the present invention can be directly used in disease treatment, for example, and various malignant tumours and cellular abnormality propagation etc.

Polypeptide of the present invention, and fragment, derivative, analogue or their cell can be used as antigen to produce antibody.These antibody can be polyclone or monoclonal antibody.Polyclonal antibody can obtain by the method with this polypeptide direct injection animal.The technology of preparation monoclonal antibody comprises hybridoma technology, three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.

Can be with polypeptide of the present invention and antagonist and suitable pharmaceutical carrier combination back use.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.

The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.

Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.Albumen with cancer suppressing function comes administration with the amount that treats and/or prevents concrete indication effectively.The proteic amount with cancer suppressing function and the dosage range that are applied to the patient will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.

The proteic polynucleotide of people with cancer suppressing function also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating since have that the proteic nothing of cancer suppressing function is expressed or the proteic expression with cancer suppressing function of unusual/non-activity due to cell proliferation, growth or metabolic disturbance.The albumen with cancer suppressing function that the gene therapy vector (as virus vector) of reorganization can be designed to express variation is to suppress endogenic protein-active with cancer suppressing function.For example, a kind of albumen with cancer suppressing function of variation can be the albumen with cancer suppressing function that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the protein expression with cancer suppressing function or the disease of active caused by abnormal.Deriving from the expression vector of virus such as protein gene that retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for having cancer suppressing function is transferred in the cell.The method that structure carries the recombinant viral vector of the protein gene with cancer suppressing function is found in existing document (Sambrook, et al.).The people protein gene of reorganization with cancer suppressing function can be packaged in the liposome and be transferred in the cell in addition.

Suppress to have cancer suppressing function people's protein mRNA oligonucleotide (comprising sense-rna and DNA) and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.

Polynucleotide imports tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.

Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carry out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension.

The present invention also provides the antibody at the people's proteantigen determinant with cancer suppressing function.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.

The anti-proteic antibody of people with cancer suppressing function can be used in the immunohistochemistry technology, detects the people's albumen with cancer suppressing function in the biopsy specimen.

With the also available labelled with radioisotope of the protein bound monoclonal antibody of the people with cancer suppressing function, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.

Antibody among the present invention can be used for treating or prevents and the relevant disease of people's albumen with cancer suppressing function.The antibody that gives suitable dosage can stimulate or block proteic generation of the people with cancer suppressing function or activity.

Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As have cancer suppressing function people's albumen high-affinity monoclonal antibody can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing the cell of the people's protein positive with cancer suppressing function.

Available people's albumen or the polypeptide immune animal of the production of polyclonal antibody with cancer suppressing function, as rabbit, mouse, rat etc.Multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.

Have cancer suppressing function people's protein monoclonal antibody can with hybridoma technology production (Kohler and Milstein.Nature, 1975,256:495-497).With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.PatNo.4946778) also can be used for producing the anti-proteic single-chain antibody of people with cancer suppressing function.

Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with the protein bound peptide molecule of the people with cancer suppressing function obtains.During screening, must carry out mark to people's protein molecular with cancer suppressing function.

The invention still further relates to quantitatively and detection and localization has the diagnostic testing process of people's protein level of cancer suppressing function.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The people's protein level that is detected in the test with cancer suppressing function, the disease that can have the importance of people's albumen in various diseases of cancer suppressing function with laying down a definition and be used to diagnose albumen to work with cancer suppressing function.

Proteic polynucleotide with cancer suppressing function can be used for having the diagnosis and the treatment of the protein related diseases of cancer suppressing function.Aspect diagnosis, the proteic polynucleotide with cancer suppressing function can be used for detecting have cancer suppressing function proteic expression whether or under morbid state, have an abnormal exprssion of cancer suppressing function.As the protein D NA sequence with cancer suppressing function can be used for the hybridization of biopsy specimen is had with judgement the proteic abnormal expression of cancer suppressing function.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out RNA-polymerase chain reaction (RT-PCR) amplification in vitro with the special primer of the albumen with cancer suppressing function and also can detect proteic transcription product with cancer suppressing function.

The sudden change that detection has the protein gene of cancer suppressing function also can be used for diagnosing the relevant disease of albumen with cancer suppressing function.Form with protein mutation of cancer suppressing function comprises that to have point mutation that the protein D NA sequence of cancer suppressing function compares, transposition, disappearance, reorganization and other any unusual etc. with normal wild type.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.

Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.

In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.

The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).

The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manual of BasicTechniques, Pergamon Press, New York (1988).

In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, Mendelian Inheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.

Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.

Pyrenoids thuja acid full length sequence or its fragment with cancer suppressing function of the present invention can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be disclosed according to the present invention about nucleotide sequence, especially open reading frame sequence designs primer, and with commercially available cDNA storehouse or by the prepared cDNA storehouse of ordinary method well known by persons skilled in the art as template, amplification and must relevant sequence.When sequence is longer, usually needs to carry out twice or pcr amplification repeatedly, and then the fragment that each time amplifies is stitched together by proper order.

In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This normally is cloned into carrier with it, changes cell again over to, separates obtaining relevant sequence then from the host cell after the propagation by ordinary method.

In addition, also the method for available synthetic is synthesized relevant sequence, especially fragment length more in short-term.Usually, by first synthetic a plurality of small segments, and then connect and to obtain the very long fragment of sequence.

At present, can be fully come the dna sequence dna of code book invention albumen (or its fragment, or derivatives thereof) by chemosynthesis.This dna sequence dna can be introduced then in the various dna moleculars (as carrier) and cell in this area.In addition, also can will suddenly change and introduce in the protein sequence of the present invention by chemosynthesis.

In addition, because the albumen with cancer suppressing function of the present invention has the natural acid sequence that is derived from the people, therefore, compare with the albumen of the same clan that derives from other species, estimate to have higher active and/or lower side effect (for example in the intravital immunogenicity of people lower or do not have) being applied to man-hour.

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold Spring Harbor LaboratoryPress, 1989) condition described in, or the condition of advising according to manufacturer.

The acquisition of embodiment 1:cDNA gene and the restraining effect that the cancer cells clone is formed

PP4491, PP5644, PP6068, PP6361, PP6455, PP6489, PP6614, PP6781, PP6832 and PP6933 obtain by making up the human placenta cDNA library with ordinary method.Get the placenta tissue at 3,6,10 monthly ages, (GIBCO BRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.Make up the cDNA library of above-mentioned mRNA with pCMV-script TMXRcDNA library construction test kit (Stratagene company).Wherein ThermoScript II is used MMLV-RT-Superscript II (GIBCO BRL) instead, and reverse transcription reaction carries out at 42 ℃.Transform XL 10-Gold recipient cell, obtained 1 * 10 ⁶The cDNA library of cfu/ μ g cDNA titre.The first round is picking cDNA clone at random, is probe with high abundance cDNA clone with the cDNA clone who has proved cancer inhibitor cell growth function thereafter, screening by hybridization cDNA library, weak positive and negative clone of picking.With Qiagen 96 orifice plate plasmid extraction test kits, carry out the extraction of plasmid DNA by shop instruction.Plasmid DNA and empty carrier transfection simultaneously hepatoma cell line 7721.After the 100ng DNA alcohol precipitation drying, add 6 μ lH ₂Transfection is treated in the O dissolving.Add 0.74 μ l liposome and 9.3 μ l serum-free mediums in every part of DNA sample, behind the mixing, room temperature was placed 10 minutes.Add 150 μ l serum-free mediums in every pipe, divide equally and add 3 holes and grow in 7721 cells of 96 orifice plates, placed 2 hours for 37 ℃, every hole adds 50 μ l serum-free mediums again, 37 ℃ 24 hours.Every hole is changed 100 μ l and is trained liquid entirely, 37 ℃ 24 hours, change the full training liquid 100 μ l that contain G418,37 ℃ 24～48 hours, the limit is observed, the training liquid that G418 concentration does not wait is changed on the limit.After about 2～3 times, there is the clone to form up to the microscopy cell, counting.Find that above clone has the cell clone of inhibition formation effect, the result is as shown in the table.

CDNA clone's transfectional cell (7721) clone formation situation

CDNA clones title	CDNA clones number (three repetitions)	Empty carrier clone number (three repetitions)
			?PP4491 ?PP5644 ?PP6068 ?PP6361 ?PP6455 ?PP6489 ?PP6614 ?PP6781 ?PP6832 ?PP6933	?4?????8?????12 ?2?????2?????2 ?5?????7?????8 ?19????12????1 ?12????9?????10 ?15????11????12 ?13????16????11 ?12????10????11 ?15????18????14 ?1?????8?????1	?48????38????35 ?35????39????32 ?23????2?????25 ?25????26????31 ?51????35????37 ?51????35????37 ?48????38????35 ?48????38????35 ?48????38????35 ?48????38????35

Above-mentioned cDNA clone is adopted two deoxidation cessation method, on the ABI377 automatic dna sequencer, measure the nucleotide sequence of the nearly 500bp of one end.After the analysis, be defined as novel gene cloning, carry out the other end order-checking, do not obtain full length cDNA sequence yet, the design primer checks order once more, up to obtaining full length sequence (SEQ ID NO:1,4,7,10,13,16,19,22,25,28).

Embodiment 2: PCR obtains full-length gene from placenta cDNA:

Get the placenta tissue at 3,6,10 monthly ages, (GIBCO BRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.With MMLV-RT-Superscript II (GIBCO BRL), ThermoScript II is carried out reverse transcription reaction at 42 ℃, obtains placenta cDNA.Utilize the different primer of commentaries on classics (as shown in the table) of each gene, by 97 ℃ of 3 minutes, 1 circulations; 94 ℃ 30 seconds → 60 ℃ 30 seconds → 72 ℃ 1 minute, totally 35 circulations; 72 ℃ 10 minutes, pcr amplification is carried out in 1 circulation, obtains to contain the amplified production of each protein gene of complete open reading frame sequence.Amplified production is through sequence verification, and the sequence that records with embodiment 1 conforms to, and changes amplified production over to host cell with routine techniques subsequently, thereby obtains recombinant protein.

Gene specific primer

Clone's title	Special primer 1 (5 ' → 3 ')	Special primer 2 (5 ' → 3 ')
			?PP4491 ?PP5644 ?PP6068 ?PP6361 ?PP6455 ?PP6489 ?PP6614 ?PP6781 ?PP6832 ?PP6933	?CCAGGCCTTGTTTTGTTTGT ?CTTGTTAACGGATGCCTGGT ?GTGGTCTGGTGGCATTTCTT ?GACTCTTCCCAGTGTCCTGC ?CCGGAAGGTGAAAGTGTTCT ?GGAGGTGGATCAGACAGCAT ?GGCACTAAATGGTGCTTGGT ?TGATCATCTTCCTCATCCCC ?CAGAGTAGCTGCGGTGAGTG ?CAGCTGCCCAAACAGTTTTC	?ATGATATTCGAGGCCTGGTG ?AACGCACTGTTTATTTGGGG ?CTCTTGGGTTTCCTGGTCAA ?TCACAGACACTGACCCTCCA ?GGAAAAGTGGCTCATTCCAA ?TAGCCCACAAACATGCCATA ?TTGTGCTACTGTGCCCACTC ?CTGTGGCACTGAGCTACTGG ?GGAAAGAGAGAGGGACTGGG ?AGAGGGATGGTGATGAGGTG

Embodiment 3:cDNA cloned sequence is analyzed

1.PP4491

A: nucleotide sequence, (SEQ, ID, NO:1), length: 2058bp, 1, CGACCTTTAT, TGCTGGGAGC, TGGCTTCTGT, CCCTTTCTTC, CCCCCCCCAC, GAGTCTTGCC, 61, CTTGACTTCT, GCTCTGGATT, CACTCTTCCC, TGTCGGCCGC, GCATGTGCTC, ATCCCACTCT121, CCGCTAAGCG, GGAGGCTGCT, GTTAGAGCAG, GCTGCTTCCT, GCCTAAAGCA, GGCCCTTCGG181, GGCTCGCTGC, ACACACATCT, CTGGCTCTCC, AGGCTTCGTG, TTCTGTCTTT, TCATCAGCAT241, GGCGGGGCGG, GGGGCGGGGG, GCGGGGGTGT, GTTTGGGAAT, CCCTCCCCCT, CTTACTTTTT301, CTCTTGTGGA, ACTTGGCCAC, AGTTTCTGAA, CAATGTGCCT, ACATTACCAG, CTGGTTTCAG361, TGATTCCTCT, GTGTCCCTTT, TTGGTTTCTG, GAAAGATTCT, TTGTCAACAT, TAGTAACTGA421, TACATAGAAC, CAAGGAGCAC, TCAAATAGGG, AGCCAGGAGC, CAGGGAGCTG, GTGACACTTG481, TGTGCTGTGG, GGCAGCTGGG, ATCCAGGTAA, GACCGGATTG, AAGCTTTGAA, ATTAGACTAA541, CAAAGCTCCA, GACAGCAAGA, GCCCAGGTGC, ACTGCTCACA, CCCCCACCTG, CATTTTGAAG601, TCATATTATT, TTTTGTTTTG, TTTTTTAAGA, CGGTCTGGCT, CTGTCGCCTA, AGCTGGAGTG661, TGGTGGCACG, ATCACAGCTC, ACTGCAGCCT, CCATCTCCTA, GGCTCAAGCC, ATTTTCCCAC, 721, CTCAGCCTCC, CGAGTAGCTG, GGACTACAGG, TGCACACCAC, CACACCTGGC, TAATTTTTTG, 781, TATTTTTAGT, AGAGACGGGG, GTTTCTTCCA, TGTTGCCCAG, GCTGGTCTCG, AACTCCTGGA, 841, CTCAAGCAAT, CCGCCCACCT, TGACTTCCCA, AAGTGCTGGG, ATTATGGGTG, GGTGTGAGCC, 901, ATTGCGCCCA, GCCTTGAAGT, CATGTTCTAA, ATTGTATTTG, AATTTGTGCC, TCTTTGTTTT, 961, TCCCCAAACC, AAAGCCCTCA, AATTGTAGTC, TCTGTCGGCT, TCTGCAGAAT, TCTGGAAAAT1021, GCCAGTTTTC, CTCCCCCGCC, CTTGTTTTCC, ATAAAACATA, TTTATATATT, GTGATGAGGA1081, GTACTTTCTG, AAGAGTACTT, CGTATTTTTT, TTTAATTGCC, TTGTTTGCCT, TCAACTTCCT1141, TGATTTTCAT, AGTTTACATG, GGTGTGTGTA, GGGGTGTGTG, TGTGTATGTG, TGTGGGTTAG1201, GGCTTTTTTC, GTTGCATGTG, ATGGTTCTGT, GGACATATGA, TCCCCACAAA, CTGTGGGAGT1261, GATTGGCCAG, GCCTTGTTTT, GTTTGTTTGT, TTGTTTGTGT, TTTTGTTCTT, TTGAAGAATA1321, GAGTGGTATT, TAGAAAATAA, ATTGCATTGC, AAAGCTCTTA, TCGGCTCATA, TGAGAGAGCA1381, GGTTCCTGCC, CTTGAAAATG, CCGGTAAGCT, ATAGCATATG, TTTTTTAAGA, CTTAAGCATT1441, TCATGCTTTA, AAATACCTTC, ACAAGTGAAC, ATTACACACA, GAAGTTCATT, TGGTTTTCCT1501, TTGTTTTATG, GTGCATATAG, CAATAAAGAC, CCCCCTCCAC, CCTGCAACCC, CCATCCCCCA1561, CCGGGCCTTT, GTCCCTGCCT, TGGCTTTTCT, CCCCTTCTCA, TTCTCCTCTC, CCCTTTCCTC1621, ACTGAAGGCT, GTGAGTTGCT, TTCAATGTGA, CAACACTATG, ATGTCATTTG, GAAGGATTTG1681, CCAGGACAGA, CTGATTCTGA, GTCCTGGGTG, CCGTATGTGT, ATGCGGCAGT, GTTGTCAGGC1741, GATCTTGTTT, GAAGCTCTAT, GTTGCCATAA, TTACCATCAA, GTACACACTG, TTGGCAAAAG1801, GCTAACACCT, GACTTTAGAA, AATGCTGATT, TGAGAACAAA, AGGAAAGGTC, TTTTTTCACT1861, GCTTAAAGTG, GGGTCACTTT, GATACCTTTG, CGGTCATGTC, TGTGTCTGAT, GAGTGTAGAA1921, TCTCTGGATG, TGCACTGTCA, GTCATGTGTC, CACCAGGCCT, CGAATATCAT, ATGGGAAATG1981, TCATAGTTAA, AAACGTACAG, CCAGGCCCGT, GTGCTGTTAA, TAGTGTGAAA, TTGTCATGTT2041, AAAAAAAAAA, AAAAAAAA

B: aminoacid sequence (SEQ ID NO:2) length: 106 amino acid/11 MVHIAIKTPL HPATPIPHRA FVPALAFLPF SFSSPLSSLK AVSCFQCDNT MMSFGRICQD61 RLILSPGCRM CMRQCCQAIL FEALCCHNYH QVHTVGKRLT PDFRKC

C. Nucleotide and amino acid composite sequence (SEQ ID NO:3)

Clone number: PP4491

Start code: 1508 ATG stop coding: 1826 TGA

protein molecular weight: 11939.69, 1, C, GAC, CTT, TAT, TGC, TGG, GAG, CTG, GCT, TCT, GTC, CCT, TTC, TTC, CCC, CCC, 46, 47, CCA, CGA, GTC, TTG, CCC, TTG, ACT, TCT, GCT, CTG, GAT, TCA, CTC, TTC, CCT, GTC, 94, 95, GGC, CGC, GCA, TGT, GCT, CAT, CCC, ACT, CTC, CGC, TAA, GCG, GGA, GGC, TGC, TGT, 142143, TAG, AGC, AGG, CTG, CTT, CCT, GCC, TAA, AGC, AGG, CCC, TTC, GGG, GCT, CGC, TGC, 190191, ACA, CAC, ATC, TCT, GGC, TCT, CCA, GGC, TTC, GTG, TTC, TGT, CTT, TTC, ATC, AGC, 238239, ATG, GCG, GGG, CGG, GGG, GCG, GGG, GGC, GGG, GGT, GTG, TTT, GGG, AAT, CCC, TCC, 286287, CCC, TCT, TAC, TTT, TTC, TCT, TGT, GGA, ACT, TGG, CCA, CAG, TTT, CTG, AAC, AAT, 334335, GTG, CCT, ACA, TTA, CCA, GCT, GGT, TTC, AGT, GAT, TCC, TCT, GTG, TCC, CTT, TTT, 382383, GGT, TTC, TGG, AAA, GAT, TCT, TTG, TCA, ACA, TTA, GTA, ACT, GAT, ACA, TAG, AAC, 430431, CAA, GGA, GCA, CTC, AAA, TAG, GGA, GCC, AGG, AGC, CAG, GGA, GCT, GGT, GAC, ACT, 478479, TGT, GTG, CTG, TGG, GGC, AGC, TGG, GAT, CCA, GGT, AAG, ACC, GGA, TTG, AAG, CTT, 526527, TGA, AAT, TAG, ACT, AAC, AAA, GCT, CCA, GAC, AGC, AAG, AGC, CCA, GGT, GCA, CTG, 574575, CTC, ACA, CCC, CCA, CCT, GCA, TTT, TGA, AGT, CAT, ATT, ATT, TTT, TGT, TTT, GTT, 622623, TTT, TAA, GAC, GGT, CTG, GCT, CTG, TCG, CCT, AAG, CTG, GAG, TGT, GGT, GGC, ACG, 670671, ATC, ACA, GCT, CAC, TGC, AGC, CTC, CAT, CTC, CTA, GGC, TCA, AGC, CAT, TTT, CCC, 718719, ACC, TCA, GCC, TCC, CGA, GTA, GCT, GGG, ACT, ACA, GGT, GCA, CAC, CAC, CAC, ACC, 766767, TGG, CTA, ATT, TTT, TGT, ATT, TTT, AGT, AGA, GAC, GGG, GGT, TTC, TTC, CAT, GTT, 814815, GCC, CAG, GCT, GGT, CTC, GAA, CTC, CTG, GAC, TCA, AGC, AAT, CCG, CCC, ACC, TTG, 862, 863, ACT, TCC, CAA, AGT, GCT, GGG, ATT, ATG, GGT, GGG, TGT, GAG, CCA, TTG, CGC, CCA, 910, 911, GCC, TTG, AAG, TCA, TGT, TCT, AAA, TTG, TAT, TTG, AAT, TTG, TGC, CTC, TTT, GTT, 958, 959, TTT, CCC, CAA, ACC, AAA, GCC, CTC, AAA, TTG, TAG, TCT, CTG, TCG, GCT, TCT, GCA, 10061007, GAA, TTC, TGG, AAA, ATG, CCA, GTT, TTC, CTC, CCC, CGC, CCT, TGT, TTT, CCA, TAA, 10541055, AAC, ATA, TTT, ATA, TAT, TGT, GAT, GAG, GAG, TAC, TTT, CTG, AAG, AGT, ACT, TCG, 11021103, TAT, TTT, TTT, TTA, ATT, GCC, TTG, TTT, GCC, TTC, AAC, TTC, CTT, GAT, TTT, CAT, 11501151, AGT, TTA, CAT, GGG, TGT, GTG, TAG, GGG, TGT, GTG, TGT, GTA, TGT, GTG, TGG, GTT, 11981199, AGG, GCT, TTT, TTC, GTT, GCA, TGT, GAT, GGT, TCT, GTG, GAC, ATA, TGA, TCC, CCA, 12461247, CAA, ACT, GTG, GGA, GTG, ATT, GGC, CAG, GCC, TTG, TTT, TGT, TTG, TTT, GTT, TGT, 12941295, TTG, TGT, TTT, TGT, TCT, TTT, GAA, GAA, TAG, AGT, GGT, ATT, TAG, AAA, ATA, AAT, 13421343, TGC, ATT, GCA, AAG, CTC, TTA, TCG, GCT, CAT, ATG, AGA, GAG, CAG, GTT, CCT, GCC, 13901391, CTT, GAA, AAT, GCC, GGT, AAG, CTA, TAG, CAT, ATG, TTT, TTT, AAG, ACT, TAA, GCA, 14381439, TTT, CAT, GCT, TTA, AAA, TAC, CTT, CAC, AAG, TGA, ACA, TTA, CAC, ACA, GAA, GTT, 14861487, CAT, TTG, GTT, TTC, CTT, TGT, TTT, ATG, GTG, CAT, ATA, GCA, ATA, AAG, ACC, CCC, 1534, 1, Met, Val, His, Ile, Ala, Ile, Lys, Thr, Pro, 91535, CTC, CAC, CCT, GCA, ACC, CCC, ATC, CCC, CAC, CGG, GCC, TTT, GTC, CCT, GCC, TTG, 1582, 10, Leu, His, Pro, Ala, Thr, Pro, Ile, Pro, His, Arg, Ala, Phe, Val, Pro, Ala, Leu, 251583, GCT, TTT, CTC, CCC, TTC, TCA, TTC, TCC, TCT, CCC, CTT, TCC, TCA, CTG, AAG, GCT, 1630, 26, Ala, Phe, Leu, Pro, Phe, Ser, Phe, Ser, Ser, Pro, Leu, Ser, Ser, Leu, Lys, Ala, 411631, GTG, AGT, TGC, TTT, CAA, TGT, GAC, AAC, ACT, ATG, ATG, TCA, TTT, GGA, AGG, ATT, 1678, 42, Val, Ser, Cys, Phe, Gln, Cys, Asp, Asn, Thr, Met, Met, Ser, Phe, Gly, Arg, Ile, 571679, TGC, CAG, GAC, AGA, CTG, ATT, CTG, AGT, CCT, GGG, TGC, CGT, ATG, TGT, ATG, CGG, 1726, 58, Cys, Gln, Asp, Arg, Leu, Ile, Leu, Ser, Pro, Gly, Cys, Arg, Met, Cys, Met, Arg, 731727, CAG, TGT, TGT, CAG, GCG, ATC, TTG, TTT, GAA, GCT, CTA, TGT, TGC, CAT, AAT, TAC, 1774, 74, Gln, Cys, Cys, Gln, Ala, Ile, Leu, Phe, Glu, Ala, Leu, Cys, Cys, His, Asn, Tyr, 891775, CAT, CAA, GTA, CAC, ACT, GTT, GGC, AAA, AGG, CTA, ACA, CCT, GAC, TTT, AGA, AAA, 1822, 90, His, Gln, Val, His, Thr, Val, Gly, Lys, Arg, Leu, Thr, Pro, Asp, Phe, Arg, Lys, 1051823, TGC, TGA, TTT, GAG, AAC, AAA, AGG, AAA, GGT, CTT, TTT, TCA, CTG, CTT, AAA, GTG, 1870, 106, Cys, * *, 1071871, GGG, TCA, CTT, TGA, TAC, CTT, TGC, GGT, CAT, GTC, TGT, GTC, TGA, TGA, GTG, TAG, 19181919, AAT, CTC, TGG, ATG, TGC, ACT, GTC, AGT, CAT, GTG, TCC, ACC, AGG, CCT, CGA, ATA, 19661967, TCA, TAT, GGG, AAA, TGT, CAT, AGT, TAA, AAA, CGT, ACA, GCC, AGG, CCC, GTG, TGC, 20142015, TGT, TAA, TAG, TGT, GAA, ATT, GTC, ATG, TTA, AAA, AAA, AAA, AAA, AAA, AA, 2058

2.PP5644

A: nucleotide sequence, (SEQ, ID, NO:4) length: 2293bp, 1, GCACGCATAG, GGGCTTGGTT, CTATGTCCCT, GTGGCTATGT, TTCCAGTGTC, CTCTGGGTGT, 61, TTCCAAGAGC, AACAAGAAAC, GAATAAATCT, CTGCCCCGCA, GCGCCTCCAC, CCCAGAGACC121, CGGACCAAGT, TCACACAGGA, CAATCTGTGC, CACGCCCAGC, GCGAGCGCCT, GGACTCGGCC181, AACCTGTGGG, TGCTGGTGGA, CTGCATCCTT, CGCGACACCT, CCGAGGACCT, GGGACTCCAG241, TGTGACGCCG, TGAACCTGGC, CTTCGGGCGC, CGCTGTGAGG, AACTGGAGGA, CGCGCGGCAC301, AAGCTGCAGC, ACCACCTGCA, CAAGGTGGGG, CACCCTTGAA, CCCCGAAGAC, GGCTCCGGCG, 361, CCTGCCCACC, ACTCTGCCCC, CTCTCATCAC, CTGGCCTGGG, CCCTCAACAC, CTTTCTCCTC, 421, TGTCCCACTT, ATCCCGAGGG, ACCCCAGAAG, CAAGTGTCAC, CTCTCCGTAA, ACCTATGTAA, 481, AACCAGGTGA, CACTGGGTAT, GATCGCAGTG, TGTTGCAACC, CCCATGACTG, AGAAGGAGGA, 541, GCTGTGGGGA, GGATGGAGGC, AGGAGCTGGT, CTGGGGAGCA, TTGACTGCCT, GGGAGGTCCC, 601, CAAGAGTCCT, GGCCTGGCAG, GCAGGGCTCT, GACTCTAGGG, CCTCAGCATG, GCCTTTACCA, 661, CCTCTGAGTC, CCCAGTCCTT, GAGCAGGATT, TGGGTCCTGG, TGACCACCAA, GGATGGGGGT, 721, TCTTGGACCA, GAGCTAAGAG, ACAACAGGCT, GCCTGACTCT, CCAGAGCCCG, CTGGGGGCCC, 781, CAGTGCACAT, TGGTTCCCCT, CACCCACGCC, TCCCCAGGGC, CACTGGTCAG, GACCACCCTC, 841, TGGACACAGC, CCCAGGAGCT, GGGTAGGACC, AGACTGGTCT, CTACATTCCA, TATGCCCGGG, 901, CATGGGGGCA, CAGGCCCAAG, GGGCACTGTC, CTGTCTGCAG, ATGCTGCGGG, AAATCACAGA, 961, TCAGGAACAC, AACGTGGTGG, CACTGAAGGA, GGCCATCAAG, GACAAGGAGG, AACCTCTGCA1021, CATAGCCCAG, ACCCGGCTGT, AGCTTGCTCT, CACACCGGCC, CAACATGCAG, CTGTCGGCGA1081, TGCACGCCCA, GTTCAGGTAC, TGCCTGGGCC, TCTGAGGCAG, TCCCAGGTGC, CCCCGTCCAC1141, CTCCTCGCTG, CGACCCTCTC, CAATAAACAC, TCCAATCTCC, ACACACACAT, CCCCCACAGG1201, TGCTGAGAGG, GGAGGGAGAC, TCTGCGGCCA, CACACAACAT, GCAAGCACGC, CTTAAACACA1261, CAGATATAGA, CATGACACTG, GGCAGGTCAT, GGGTCGGGGG, CCTCCCCGTG, CCAGGGACCT1321, GTGCCCACGT, GGTCTCACCC, CACCCTGTGC, TACCTCATCT, TCCCGGGAGG, AAGCTCCTTC1381, AGACAAGGTG, AGCTCCTGGA, GGCCACGGGG, CCAGAGAGGC, CAGAGAGGGC, CATTCCCTGC1441, TGCCCTGAGG, GTGCTGTCCC, CACCTCTGGT, GGAAAGTATG, ACCTACGCCT, GGGCTACAGG1501, CATAGATGGG, CCGTCCTTTT, GTTTCCCTTG, TTAACGGATG, CCTGGTGGCC, CCTTCTGAGC1561, CTAAGTACCT, TTCTTCCTTC, CCTGCCCCTC, AGTTCCTTCA, AGGAACTGGG, TGCCTCCTTC1621, CGTCAAATAT, CAGGAATGGA, AAGAACTGAG, CCTGGTCGGC, TGAGGCCAGT, CCTGTCCTGT1681, CAGGGTCGAG, ATTGCACGCG, GGTCACTCAT, TCCCACTCAG, GTCCGCGCTC, CCTGGGAGGA1741, CCCTCGTAAT, TTATGCTCTG, CCCTAGAGCC, GCTTTCCTGG, TAGGATCCTT, TCATGGCGTC1801, TTCCCAGGAC, CTCCTGCCAG, CTCCCATTGG, GAGTTTTGGG, TCCCCTCCAC, CCCAGTAGGT1861, GCATACTTCT, GCCCTCCCCA, GCCCCAGCTC, ACACCCCCCA, ACACCCCCAA, GCTGGTGAGT1921, GAGGTGGAGG, AGCTGTACAA, GTCCATCACA, GCGCTGCGGG, AGAAGCTTCT, ACAAGCGGAG1981, CAGTCCCTGC, GCAACCTCAA, GGACATCCAC, ATGAGCCTGG, AGAAGGACGT, CACCGCCATG2041, ACCAACAGTG, TCTTCATCGA, CCGCCAGAAG, TGCATGGCCC, ATCGTACTTG, CTACCCCACC2101, ATTCTGCAGC, TGGCTGGCTA, CCAGTGAGCA, GCGGCACGGT, GCTTCCCCCC, AATCCCCCAA2161, ATAAACAGTG, CGTTAGTTTC, TGCAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA2221, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA2281, AAAAAAAAAA, AAA

B: aminoacid sequence (SEQ ID NO:5) length: 124 amino acid/11 MLCPRAAFLV GSFHGVFPGP PASSHWEFWV PSTPVGAYFC PPQPQLTPPN TPKLVSEVEE 61 LYKSITALRE KLLQAEQSLR NLKDIHMSLE KDVTAMTNSV FIDRQKCMAH RTCYPTILQL121 AGYQ

C. Nucleotide and amino acid composite sequence (SEQ ID NO:6)

Clone number: PP5644

Start code: 1753 ATG stop coding: 2125 TGA

protein molecular weight: 13946.47, 1, GCA, CGC, ATA, GGG, GCT, TGG, TTC, TAT, GTC, CCT, GTG, GCT, ATG, TTT, CCA, GTG, 48, 49, TCC, TCT, GGG, TGT, TTC, CAA, GAG, CAA, CAA, GAA, ACG, AAT, AAA, TCT, CTG, CCC, 96, 97, CGC, AGC, GCC, TCC, ACC, CCA, GAG, ACC, CGG, ACC, AAG, TTC, ACA, CAG, GAC, AAT, 144145, CTG, TGC, CAC, GCC, CAG, CGC, GAG, CGC, CTG, GAC, TCG, GCC, AAC, CTG, TGG, GTG, 192193, CTG, GTG, GAC, TGC, ATC, CTT, CGC, GAC, ACC, TCC, GAG, GAC, CTG, GGA, CTC, CAG, 240241, TGT, GAC, GCC, GTG, AAC, CTG, GCC, TTC, GGG, CGC, CGC, TGT, GAG, GAA, CTG, GAG, 288289, GAC, GCG, CGG, CAC, AAG, CTG, CAG, CAC, CAC, CTG, CAC, AAG, GTG, GGG, CAC, CCT, 336337, TGA, ACC, CCG, AAG, ACG, GCT, CCG, GCG, CCT, GCC, CAC, CAC, TCT, GCC, CCC, TCT, 384, 385, CAT, CAC, CTG, GCC, TGG, GCC, CTC, AAC, ACC, TTT, CTC, CTC, TGT, CCC, ACT, TAT, 432, 433, CCC, GAG, GGA, CCC, CAG, AAG, CAA, GTG, TCA, CCT, CTC, CGT, AAA, CCT, ATG, TAA, 480, 481, AAC, CAG, GTG, ACA, CTG, GGT, ATG, ATC, GCA, GTG, TGT, TGC, AAC, CCC, CAT, GAC, 528, 529, TGA, GAA, GGA, GGA, GCT, GTG, GGG, AGG, ATG, GAG, GCA, GGA, GCT, GGT, CTG, GGG, 576, 577, AGC, ATT, GAC, TGC, CTG, GGA, GGT, CCC, CAA, GAG, TCC, TGG, CCT, GGC, AGG, CAG, 624, 625, GGC, TCT, GAC, TCT, AGG, GCC, TCA, GCA, TGG, CCT, TTA, CCA, CCT, CTG, AGT, CCC, 672, 673, CAG, TCC, TTG, AGC, AGG, ATT, TGG, GTC, CTG, GTG, ACC, ACC, AAG, GAT, GGG, GGT, 720, 721, TCT, TGG, ACC, AGA, GCT, AAG, AGA, CAA, CAG, GCT, GCC, TGA, CTC, TCC, AGA, GCC, 768, 769, CGC, TGG, GGG, CCC, CAG, TGC, ACA, TTG, GTT, CCC, CTC, ACC, CAC, GCC, TCC, CCA, 816, 817, GGG, CCA, CTG, GTC, AGG, ACC, ACC, CTC, TGG, ACA, CAG, CCC, CAG, GAG, CTG, GGT, 864, 865, AGG, ACC, AGA, CTG, GTC, TCT, ACA, TTC, CAT, ATG, CCC, GGG, CAT, GGG, GGC, ACA, 912, 913, GGC, CCA, AGG, GGC, ACT, GTC, CTG, TCT, GCA, GAT, GCT, GCG, GGA, AAT, CAC, AGA, 960, 961, TCA, GGA, ACA, CAA, CGT, GGT, GGC, ACT, GAA, GGA, GGC, CAT, CAA, GGA, CAA, GGA, 10081009, GGA, ACC, TCT, GCA, CAT, AGC, CCA, GAC, CCG, GCT, GTA, GCT, TGC, TCT, CAC, ACC, 10561057, GGC, CCA, ACA, TGC, AGC, TGT, CGG, CGA, TGC, ACG, CCC, AGT, TCA, GGT, ACT, GCC, 11041105, TGG, GCC, TCT, GAG, GCA, GTC, CCA, GGT, GCC, CCC, GTC, CAC, CTC, CTC, GCT, GCG, 11521153, ACC, CTC, TCC, AAT, AAA, CAC, TCC, AAT, CTC, CAC, ACA, CAC, ATC, CCC, CAC, AGG, 12001201, TGC, TGA, GAG, GGG, AGG, GAG, ACT, CTG, CGG, CCA, CAC, ACA, ACA, TGC, AAG, CAC, 12481249, GCC, TTA, AAC, ACA, CAG, ATA, TAG, ACA, TGA, CAC, TGG, GCA, GGT, CAT, GGG, TCG, 12961297, GGG, GCC, TCC, CCG, TGC, CAG, GGA, CCT, GTG, CCC, ACG, TGG, TCT, CAC, CCC, ACC, 13441345, CTG, TGC, TAC, CTC, ATC, TTC, CCG, GGA, GGA, AGC, TCC, TTC, AGA, CAA, GGT, GAG, 13921393, CTC, CTG, GAG, GCC, ACG, GGG, CCA, GAG, AGG, CCA, GAG, AGG, GCC, ATT, CCC, TGC, 14401441, TGC, CCT, GAG, GGT, GCT, GTC, CCC, ACC, TCT, GGT, GGA, AAG, TAT, GAC, CTA, CGC, 14881489, CTG, GGC, TAC, AGG, CAT, AGA, TGG, GCC, GTC, CTT, TTG, TTT, CCC, TTG, TTA, ACG, 15361537, GAT, GCC, TGG, TGG, CCC, CTT, CTG, AGC, CTA, AGT, ACC, TTT, CTT, CCT, TCC, CTG, 15841585, CCC, CTC, AGT, TCC, TTC, AAG, GAA, CTG, GGT, GCC, TCC, TTC, CGT, CAA, ATA, TCA, 16321633, GGA, ATG, GAA, AGA, ACT, GAG, CCT, GGT, CGG, CTG, AGG, CCA, GTC, CTG, TCC, TGT, 16801681, CAG, GGT, CGA, GAT, TGC, ACG, CGG, GTC, ACT, CAT, TCC, CAC, TCA, GGT, CCG, CGC, 17281729, TCC, CTG, GGA, GGA, CCC, TCG, TAA, TTT, ATG, CTC, TGC, CCT, AGA, GCC, GCT, TTC, 1776, 1, Met, Leu, Cys, Pro, Arg, Ala, Ala, Phe, 81777, CTG, GTA, GGA, TCC, TTT, CAT, GGC, GTC, TTC, CCA, GGA, CCT, CCT, GCC, AGC, TCC, 1824, 9, Leu, Val, Gly, Ser, Phe, His, Gly, Val, Phe, Pro, Gly, Pro, Pro, Ala, Ser, Ser, 241825, CAT, TGG, GAG, TTT, TGG, GTC, CCC, TCC, ACC, CCA, GTA, GGT, GCA, TAC, TTC, TGC, 1872, 25, His, Trp, Glu, Phe, Trp, Val, Pro, Ser, Thr, Pro, Val, Gly, Ala, Tyr, Phe, Cys, 401873, CCT, CCC, CAG, CCC, CAG, CTC, ACA, CCC, CCC, AAC, ACC, CCC, AAG, CTG, GTG, AGT, 1920, 41, Pro, Pro, Gln, Pro, Gln, Leu, Thr, Pro, Pro, Asn, Thr, Pro, Lys, Leu, Val, Ser, 561921, GAG, GTG, GAG, GAG, CTG, TAC, AAG, TCC, ATC, ACA, GCG, CTG, CGG, GAG, AAG, CTT, 1968, 57, Glu, Val, Glu, Glu, Leu, Tyr, Lys, Ser, Ile, Thr, Ala, Leu, Arg, Glu, Lys, Leu, 721969, CTA, CAA, GCG, GAG, CAG, TCC, CTG, CGC, AAC, CTC, AAG, GAC, ATC, CAC, ATG, AGC, 2016, 73, Leu, Gln, Ala, Glu, Gln, Ser, Leu, Arg, Asn, Leu, Lys, Asp, Ile, His, Met, Ser, 882017, CTG, GAG, AAG, GAC, GTC, ACC, GCC, ATG, ACC, AAC, AGT, GTC, TTC, ATC, GAC, CGC, 2064, 89, Leu, Glu, Lys, Asp, Val, Thr, Ala, Met, Thr, Asn, Ser, Val, Phe, Ile, Asp, Arg, 1042065, CAG, AAG, TGC, ATG, GCC, CAT, CGT, ACT, TGC, TAC, CCC, ACC, ATT, CTG, CAG, CTG, 2112, 105, Gln, Lys, Cys, Met, Ala, His, Arg, Thr, Cys, Tyr, Pro, Thr, Ile, Leu, Gln, Leu, 1202113, GCT, GGC, TAC, CAG, TGA, GCA, GCG, GCA, CGG, TGC, TTC, CCC, CCA, ATC, CCC, CAA, 2160, 121, Ala, Gly, Tyr, Gln, * *, 1252161, ATA, AAC, AGT, GCG, TTA, GTT, TCT, GCA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, 22082209, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, 22562257, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, A, 2293

3.PP6068

A: nucleotide sequence, (SEQ, ID, NO:7) length: 1851bp, 1, GAAATTCCAC, AGCTCCCGTC, CTGGCCACCC, TGGAAGCTCA, TCAGGCCAAG, ACCCGGACAG, 61, AGCTTCAGAG, GAGTGTTGAG, TGACACCTGA, GGATGCGGCT, GCACACACTC, AGCCAAGGGC, 121, CGAGTCTCAC, CTGCGGTGGG, GTTTCGGCTC, TGCCTGGGGG, CTCCATCCCT, TTCAGCCACT, 181, CGTGGCCTTG, GGGATTTCTG, GTTGTCCCCA, GCTGGGACTG, TTCACAGTTG, TCACCTGCAG, 241, ACCTGCCTCT, CCCTGGCCTG, AGGTTCAAAG, GCCTCATCGG, ATGGTCAGTA, CAGTGGGGTC, 301, ACCTGTTGTT, TCTATACAAC, AGCAGGGAAG, GGGCCATGGA, GCTTTTCCCT, GCTGGGTGCT, 361, CCTGCTTTGG, CCCAGCCCAC, CTTTCCTGGT, GCTCCAAGCT, AGGAGGCTGT, GGCCCCAGCC, 421, TGAGGAGGGT, GTCCTGGCCT, CCAGGTGTGC, AGCAGGGGCT, GTGTGCTGGG, GGAGGTTCCA, 481, GTTAGGCGAT, GGGATCCTGC, AGTGGTCTGG, TGGCATTTCT, TGGAACCAGA, TTTACCTGAG, 541, GAGCTCTGTC, CTGCTCCCTG, TGGAGGGCTC, CAGATAGCTC, AGAAATGACC, AGCCAATGGC, 601, CTTTTGTTTG, GGGGCCTGAG, GTCAAGAGAG, CTGAGAGTAT, TCGCTCGACT, GAGCACATTC, 661, AGGAAGATCA, GGGCAGGCGT, GTGGGAGGTC, CCTCACTCCA, CGGGACAGAG, GCCCCTGGAC, 721, AGCAGAGGAA, ACCTACAGCT, CTGGGTGAGG, GGACACTTGG, CTTTGGTGTT, TGCACTTTAC, 781, AGATCCTGCG, GTCCACGAGG, GGCCTCAGGA, GAGGACGTGT, CAGGACGTGG, CTTCCCAGCC, 841, TTCTGCCTTG, GGCAGTGGGG, GTGCTCCTGT, CTGTCCTTTT, CCCCCACACC, CTGGACTGTG, 901, CTTGGCTGTT, GGTGCACATG, GTTGGCACAC, GGTGGGCAGA, GGGCAGAGAA, TGCCACTGCT, 961, TGGTTATTGG, TCCCCTTTGA, CCAGGAAACC, CAAGAGGAGA, CACCTCAGTC, AGCAGAAAGG1021, CCACCTGGCT, CACTGGCTCA, TTCCAGGAGT, GGGAGAGACG, GCAGGGTCTC, CTCTTTGTCC1081, TCCGGCATCA, GGAAGGGGAT, GGTGTCCACT, CCCCACTGTG, GTGGCTTTAG, GCAAGGTTCT1141, TATTGTCTGC, TCTGCCTCGG, TTTCCCCATC, TGGAAAATGG, GGGCAGGGGT, CCTGACCTAC1201, CTCAGGTGGA, ACGGTGAGCA, GGGAACATGT, CGGAGTCCTT, CAGAGAATGT, GATGTGAGGT1261, TGGATCAACA, GTGTGGGTTC, CTGTCCTGTT, TCCCCTTCCT, CTTTGGGGCT, GAGGAGGAGG1321, TTAAAGGCCA, AATGCTGTTT, CCCAACACCC, CAAAGTCTGC, ACACGTCTCA, TGAATGCATC1381, ACATTTCTGT, CATATGGATA, TTAGCCATTC, CGAAATCTGT, GTAATCAACT, TCACATTATT1441, CAAGTTACAA, ATCACTGTGT, CCATAGAAAA, ACTGTGCTGG, TATTTGCTGG, ACAAAGGGTT1501, GGGCCCCTTT, TATTTTTACC, TGCCACCCAG, CATCTCCCCC, ACCTGCCCCT, TCTGGGTGAC1561, ACAGCCGGTA, AACGGAATCA, CGTATGGTTC, TTTCTGTGGG, TCTGTGGCAC, AGCAGGAAGA1621, GCCCGGTGCC, GCCAGCACCT, TGTGGAAGAC, CACACATGGG, TGGTCCCACA, GCATGGGACC1681, AGGCTGGCCT, GAGGGATGCC, CAGTTGTAAC, AATGCTGCTG, TCACTGTCTC, ATTAAATATA1741, CATCCTTTAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA1801, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, AAAAAAAAAA, A

B: aminoacid sequence (SEQ ID NO:8) length: 131 amino acid/11 MTSQWPFVWG PEVKRAESIR STEHIQEDQG RRVGGPSLHG TEAPGQQRKP TALGEGTLGF 61 GVCTLQILRS TRGLRRGRVR TWLPSLLPWA VGVLLSVLFP HTLDCAWLLV HMVGTRWAEG121 RECHCLVIGP L

C. Nucleotide and amino acid composite sequence (SEQ ID NO:9)

Clone number: PP6068

Start code: 585 ATG stop coding: 978 TGA

protein molecular weight: 14556.15, 1, GA, AAT, TCC, ACA, GCT, CCC, GTC, CTG, GCC, ACC, CTG, GAA, GCT, CAT, CAG, GCC, 47, 48, AAG, ACC, CGG, ACA, GAG, CTT, CAG, AGG, AGT, GTT, GAG, TGA, CAC, CTG, AGG, ATG, 95, 96, CGG, CTG, CAC, ACA, CTC, AGC, CAA, GGG, CCG, AGT, CTC, ACC, TGC, GGT, GGG, GTT, 143, 144, TCG, GCT, CTG, CCT, GGG, GGC, TCC, ATC, CCT, TTC, AGC, CAC, TCG, TGG, CCT, TGG, 191, 192, GGA, TTT, CTG, GTT, GTC, CCC, AGC, TGG, GAC, TGT, TCA, CAG, TTG, TCA, CCT, GCA, 239, 240, GAC, CTG, CCT, CTC, CCT, GGC, CTG, AGG, TTC, AAA, GGC, CTC, ATC, GGA, TGG, TCA, 287, 288, GTA, CAG, TGG, GGT, CAC, CTG, TTG, TTT, CTA, TAC, AAC, AGC, AGG, GAA, GGG, GCC, 335, 336, ATG, GAG, CTT, TTC, CCT, GCT, GGG, TGC, TCC, TGC, TTT, GGC, CCA, GCC, CAC, CTT, 383, 384, TCC, TGG, TGC, TCC, AAG, CTA, GGA, GGC, TGT, GGC, CCC, AGC, CTG, AGG, AGG, GTG, 431, 432, TCC, TGG, CCT, CCA, GGT, GTG, CAG, CAG, GGG, CTG, TGT, GCT, GGG, GGA, GGT, TCC, 479, 480, AGT, TAG, GCG, ATG, GGA, TCC, TGC, AGT, GGT, CTG, GTG, GCA, TTT, CTT, GGA, ACC, 527, 528, AGA, TTT, ACC, TGA, GGA, GCT, CTG, TCC, TGC, TCC, CTG, TGG, AGG, GCT, CCA, GAT, 575, 576, AGC, TCA, GAA, ATG, ACC, AGC, CAA, TGG, CCT, TTT, GTT, TGG, GGG, CCT, GAG, GTC, 623, 1, Met, Thr, Ser, Gln, Trp, Pro, Phe, Val, Trp, Gly, Pro, Glu, Val, 13, 624, AAG, AGA, GCT, GAG, AGT, ATT, CGC, TCG, ACT, GAG, CAC, ATT, CAG, GAA, GAT, CAG, 671, 14, Lys, Arg, Ala, Glu, Ser, Ile, Arg, Ser, Thr, Glu, His, Ile, Gln, Glu, Asp, Gln, 29, 672, GGC, AGG, CGT, GTG, GGA, GGT, CCC, TCA, CTC, CAC, GGG, ACA, GAG, GCC, CCT, GGA, 719, 30, Gly, Arg, Arg, Val, Gly, Gly, Pro, Ser, Leu, His, Gly, Thr, Glu, Ala, Pro, Gly, 45, 720, CAG, CAG, AGG, AAA, CCT, ACA, GCT, CTG, GGT, GAG, GGG, ACA, CTT, GGC, TTT, GGT, 767, 46, Gln, Gln, Arg, Lys, Pro, Thr, Ala, Leu, Gly, Glu, Gly, Thr, Leu, Gly, Phe, Gly, 61, 768, GTT, TGC, ACT, TTA, CAG, ATC, CTG, CGG, TCC, ACG, AGG, GGC, CTC, AGG, AGA, GGA, 815, 62, Val, Cys, Thr, Leu, Gln, Ile, Leu, Arg, Ser, Thr, Arg, Gly, Leu, Arg, Arg, Gly, 77, 816, CGT, GTC, AGG, ACG, TGG, CTT, CCC, AGC, CTT, CTG, CCT, TGG, GCA, GTG, GGG, GTG, 863, 78, Arg, Val, Arg, Thr, Trp, Leu, Pro, Ser, Leu, Leu, Pro, Trp, Ala, Val, Gly, Val, 93, 864, CTC, CTG, TCT, GTC, CTT, TTC, CCC, CAC, ACC, CTG, GAC, TGT, GCT, TGG, CTG, TTG, 911, 94, Leu, Leu, Ser, Val, Leu, Phe, Pro, His, Thr, Leu, Asp, Cys, Ala, Trp, Leu, Leu, 109, 912, GTG, CAC, ATG, GTT, GGC, ACA, CGG, TGG, GCA, GAG, GGC, AGA, GAA, TGC, CAC, TGC, 959, 110, Val, His, Met, Val, Gly, Thr, Arg, Trp, Ala, Glu, Gly, Arg, Glu, Cys, His, Cys, 125, 960, TTG, GTT, ATT, GGT, CCC, CTT, TGA, CCA, GGA, AAC, CCA, AGA, GGA, GAC, ACC, TCA, 1007, 126, Leu, Val, Ile, Gly, Pro, Leu, * *, 1321008, GTC, AGC, AGA, AAG, GCC, ACC, TGG, CTC, ACT, GGC, TCA, TTC, CAG, GAG, TGG, GAG, 10551056, AGA, CGG, CAG, GGT, CTC, CTC, TTT, GTC, CTC, CGG, CAT, CAG, GAA, GGG, GAT, GGT, 11031104, GTC, CAC, TCC, CCA, CTG, TGG, TGG, CTT, TAG, GCA, AGG, TTC, TTA, TTG, TCT, GCT, 11511152, CTG, CCT, CGG, TTT, CCC, CAT, CTG, GAA, AAT, GGG, GGC, AGG, GGT, CCT, GAC, CTA, 11991200, CCT, CAG, GTG, GAA, CGG, TGA, GCA, GGG, AAC, ATG, TCG, GAG, TCC, TTC, AGA, GAA, 12471248, TGT, GAT, GTG, AGG, TTG, GAT, CAA, CAG, TGT, GGG, TTC, CTG, TCC, TGT, TTC, CCC, 12951296, TTC, CTC, TTT, GGG, GCT, GAG, GAG, GAG, GTT, AAA, GGC, CAA, ATG, CTG, TTT, CCC, 13431344, AAC, ACC, CCA, AAG, TCT, GCA, CAC, GTC, TCA, TGA, ATG, CAT, CAC, ATT, TCT, GTC, 13911392, ATA, TGG, ATA, TTA, GCC, ATT, CCG, AAA, TCT, GTG, TAA, TCA, ACT, TCA, CAT, TAT, 14391440, TCA, AGT, TAC, AAA, TCA, CTG, TGT, CCA, TAG, AAA, AAC, TGT, GCT, GGT, ATT, TGC, 14871488, TGG, ACA, AAG, GGT, TGG, GCC, CCT, TTT, ATT, TTT, ACC, TGC, CAC, CCA, GCA, TCT, 15351536, CCC, CCA, CCT, GCC, CCT, TCT, GGG, TGA, CAC, AGC, CGG, TAA, ACG, GAA, TCA, CGT, 15831584, ATG, GTT, CTT, TCT, GTG, GGT, CTG, TGG, CAC, AGC, AGG, AAG, AGC, CCG, GTG, CCG, 16311632, CCA, GCA, CCT, TGT, GGA, AGA, CCA, CAC, ATG, GGT, GGT, CCC, ACA, GCA, TGG, GAC, 16791680, CAG, GCT, GGC, CTG, AGG, GAT, GCC, CAG, TTG, TAA, CAA, TGC, TGC, TGT, CAC, TGT, 17271728, CTC, ATT, AAA, TAT, ACA, TCC, TTT, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, 17751776, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, 18231824, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, A, 1851

4.PP6361

A: nucleotide sequence, (SEQ, ID, NO:10), length: 1630bp, 1, GGTGATGGTG, GTGGCAGGTG, TGGTGGTGCT, GATTCTAGCC, TTGGTCCTAG, CTTGGCTCTC, 61, TACCTACGTA, GCAGACAGCG, GTAGCAACCA, GCTCCTGGGC, GCTATTGTGT, CAGCAGGCGA, 121, CACATCCGTC, CTCCACCTGG, GGCATGTGGA, CCACCTGGTG, GCAGGCCAAG, GCAACCCCGA, 181, GCCAACTGAA, CTCCCCCATC, CATCAGAGGA, CAAGCAGGTG, CAGGCAGCAG, CAGTCCAGAG, 241, GCCCCCCTGA, GATCTGAGGA, TAGCACCTGC, CTCCCTCCCA, GCCCTGGCCT, CATCACTGTG, 301, CGGCTCAAAT, TCCTCAATGA, TACCGAGGAG, CTGGCTGTGG, CTAGGCCAGA, GGATACCGTG, 361, GGTGCCCTGA, AGAGCAAATA, CTTCCCTGGA, CAAGAAAGCC, AGATGAAACT, GATCTACCAG, 421, GGCCGCCTGC, TACAAGACCC, AGCCCGCACA, CTGCGTTCTC, TGAACATTAC, CGACAACTGT, 481, GTGATTCACT, GCCACCGCTC, ACCCCCAGGG, TCAGCTGTTC, CAGGCCCCTC, AGCCTCCTTG, 541, GCCCCCTCGG, CCACTGAGCC, ACCCAGCCTT, GGTGTCAATG, TGGGCAGCCT, CATGGTGCCT, 601, GTCTTTGTGG, TGCTGTTGGG, TGTGGTCTGG, TACTTCCGAA, TCAATTACCG, CCAATTCTTC, 661, ACAGCACCTG, CCACTGTCTC, CCTGGTGGGA, GTCACCGTCT, TCTTCAGCTT, CCTAGTATTT, 721, GGGATGTATG, GACGATAAGG, ACATAGGAAG, AAAATGAAAG, GCATGGTCTT, TCTCCTTTAT, 781, GGCCTCCCCA, CTTTTCCTGG, CCAGAGCTGG, GCCCAAGGGC, CGGGGAGGGA, GGGGTGGAAA, 841, GGATGTGATG, GAAATCTCCT, CCATAGGACA, CAGGAGGCAA, GTATGCGGCC, TCCCCTTCTC, 901, ATCCACAGGA, GTACAGATGT, CCCTCCCGTG, CGAGCACAAC, TCAGGTAGAA, ATGAGGATGT, 961, CATCTTCCTT, CACTTTTAGG, GTCCTCTGAA, GGAGTTCAAA, GCTGCTGGCC, AAGCTCAGTG1021, GGGAGCCTGG, GCTCTGAGAT, TCCCTCCCAC, CTGTGGTTCT, GACTCTTCCC, AGTGTCCTGC1081, ATGTCTGCCC, CCAGCACCCA, GGGCTGCCTG, CAAGGGCAGC, TCAGCATGGC, CCCAGCACAA1141, CTCCGTAGGG, AGCCTGGAGT, ATCCTTCCAT, TTCTCAGCCA, AATACTCATC, TTTTGAGACT1201, GAAATCACAC, TGGCGGGAAT, GAAGATTGTG, CCAGCCTTCT, CTTATGGGCA, CCTAGCCGCC1261, TTCACCTTCT, TCCTCTACCC, CTTAGCAGGA, ATAGGGTGTC, CTCCCTTCTT, TCAAAGCACT1321, TTGCTTGCAT, TTTATTTTAT, TTTTTTAAGA, GTCCTTCATA, GAGCTCAGTC, AGGAAGGGGA1381, TGGGGCACCA, AGCCAAGCCC, CCAGCATTGG, GAGCGGCCAG, GCCACAGCTG, CTGCTCCCGT1441, AGTCCTCAGG, CTGTAAGCAA, GAGACAGCAC, TGGCCCTTGG, CCAGCGTCCT, ACCCTGCCCA1501, ACTCCAAGGA, CTGGGTATGG, ATCGCTGGGC, CCTAGGCTCT, TGCTTCTGGG, GCTATTGGAG1561, GGTCAGTGTC, TGTGACTGAA, TAAAGTTCCA, TTTTGTGGTC, CTGCAAAAAA, AAAAAAAAAA1621, AAAAAAAAAA

B: aminoacid sequence (SEQ ID NO:11) length: 164 amino acid/11 MSAPSTQGCL QGQLSMAPAQ LRREPGVSFH FSAKYSSFET EITLAGMKIV PAFSYGHLAA 61 FTFFLYPLAG IGCPPFFQST LLAFYFIFLR VLHRAQSGRG WGTKPSPQHW ERPGHSCCSR121 SPQAVSKRQH WPLASVLPCP TPRTGYGSLG PRLLLLGLLE GQCL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:12)

Clone number: PP6361

Start code: 1081 ATG stop coding: 1573 TGA

protein molecular weight: 17998.95, 1, GGT, GAT, GGT, GGT, GGC, AGG, TGT, GGT, GGT, GCT, GAT, TCT, AGC, CTT, GGT, CCT, 4849, AGC, TTG, GCT, CTC, TAC, CTA, CGT, AGC, AGA, CAG, CGG, TAG, CAA, CCA, GCT, CCT, 96, 97, GGG, CGC, TAT, TGT, GTC, AGC, AGG, CGA, CAC, ATC, CGT, CCT, CCA, CCT, GGG, GCA, 144, 145, TGT, GGA, CCA, CCT, GGT, GGC, AGG, CCA, AGG, CAA, CCC, CGA, GCC, AAC, TGA, ACT, 192, 193, CCC, CCA, TCC, ATC, AGA, GGA, CAA, GCA, GGT, GCA, GGC, AGC, AGC, AGT, CCA, GAG, 240, 241, GCC, CCC, CTG, AGA, TCT, GAG, GAT, AGC, ACC, TGC, CTC, CCT, CCC, AGC, CCT, GGC, 288, 289, CTC, ATC, ACT, GTG, CGG, CTC, AAA, TTC, CTC, AAT, GAT, ACC, GAG, GAG, CTG, GCT, 336, 337, GTG, GCT, AGG, CCA, GAG, GAT, ACC, GTG, GGT, GCC, CTG, AAG, AGC, AAA, TAC, TTC, 384, 385, CCT, GGA, CAA, GAA, AGC, CAG, ATG, AAA, CTG, ATC, TAC, CAG, GGC, CGC, CTG, CTA, 432, 433, CAA, GAC, CCA, GCC, CGC, ACA, CTG, CGT, TCT, CTG, AAC, ATT, ACC, GAC, AAC, TGT, 480, 481, GTG, ATT, CAC, TGC, CAC, CGC, TCA, CCC, CCA, GGG, TCA, GCT, GTT, CCA, GGC, CCC, 528, 529, TCA, GCC, TCC, TTG, GCC, CCC, TCG, GCC, ACT, GAG, CCA, CCC, AGC, CTT, GGT, GTC, 576, 577, AAT, GTG, GGC, AGC, CTC, ATG, GTG, CCT, GTC, TTT, GTG, GTG, CTG, TTG, GGT, GTG, 624, 625, GTC, TGG, TAC, TTC, CGA, ATC, AAT, TAC, CGC, CAA, TTC, TTC, ACA, GCA, CCT, GCC, 672, 673, ACT, GTC, TCC, CTG, GTG, GGA, GTC, ACC, GTC, TTC, TTC, AGC, TTC, CTA, GTA, TTT, 720, 721, GGG, ATG, TAT, GGA, CGA, TAA, GGA, CAT, AGG, AAG, AAA, ATG, AAA, GGC, ATG, GTC, 768, 769, TTT, CTC, CTT, TAT, GGC, CTC, CCC, ACT, TTT, CCT, GGC, CAG, AGC, TGG, GCC, CAA, 816, 817, GGG, CCG, GGG, AGG, GAG, GGG, TGG, AAA, GGA, TGT, GAT, GGA, AAT, CTC, CTC, CAT, 864, 865, AGG, ACA, CAG, GAG, GCA, AGT, ATG, CGG, CCT, CCC, CTT, CTC, ATC, CAC, AGG, AGT, 912, 913, ACA, GAT, GTC, CCT, CCC, GTG, CGA, GCA, CAA, CTC, AGG, TAG, AAA, TGA, GGA, TGT, 960, 961, CAT, CTT, CCT, TCA, CTT, TTA, GGG, TCC, TCT, GAA, GGA, GTT, CAA, AGC, TGC, TGG, 10081009, CCA, AGC, TCA, GTG, GGG, AGC, CTG, GGC, TCT, GAG, ATT, CCC, TCC, CAC, CTG, TGG, 10561057, TTC, TGA, CTC, TTC, CCA, GTG, TCC, TGC, ATG, TCT, GCC, CCC, AGC, ACC, CAG, GGC, 1104, 1, Met, Ser, Ala, Pro, Ser, Thr, Gln, Gly, 81105, TGC, CTG, CAA, GGG, CAG, CTC, AGC, ATG, GCC, CCA, GCA, CAA, CTC, CGT, AGG, GAG, 1152, 9, Cys, Leu, Gln, Gly, Gln, Leu, Ser, Met, Ala, Pro, Ala, Gln, Leu, Arg, Arg, Glu, 241153, CCT, GGA, GTA, TCC, TTC, CAT, TTC, TCA, GCC, AAA, TAC, TCA, TCT, TTT, GAG, ACT, 1200, 25, Pro, Gly, Val, Ser, Phe, His, Phe, Ser, Ala, Lys, Tyr, Ser, Ser, Phe, Glu, Thr, 401201, GAA, ATC, ACA, CTG, GCG, GGA, ATG, AAG, ATT, GTG, CCA, GCC, TTC, TCT, TAT, GGG, 1248, 41, Glu, Ile, Thr, Leu, Ala, Gly, Met, Lys, Ile, Val, Pro, Ala, Phe, Ser, Tyr, Gly, 561249, CAC, CTA, GCC, GCC, TTC, ACC, TTC, TTC, CTC, TAC, CCC, TTA, GCA, GGA, ATA, GGG, 1296, 57, His, Leu, Ala, Ala, Phe, Thr, Phe, Phe, Leu, Tyr, Pro, Leu, Ala, Gly, Ile, Gly, 721297, TGT, CCT, CCC, TTC, TTT, CAA, AGC, ACT, TTG, CTT, GCA, TTT, TAT, TTT, ATT, TTT, 1344, 73, Cys, Pro, Pro, Phe, Phe, Gln, Ser, Thr, Leu, Leu, Ala, Phe, Tyr, Phe, Ile, Phe, 881345, TTA, AGA, GTC, CTT, CAT, AGA, GCT, CAG, TCA, GGA, AGG, GGA, TGG, GGC, ACC, AAG, 1392, 89, Leu, Arg, Val, Leu, His, Arg, Ala, Gln, Ser, Gly, Arg, Gly, Trp, Gly, Thr, Lys, 1041393, CCA, AGC, CCC, CAG, CAT, TGG, GAG, CGG, CCA, GGC, CAC, AGC, TGC, TGC, TCC, CGT, 1440, 105, Pro, Ser, Pro, Gln, His, Trp, Glu, Arg, Pro, Gly, His, Ser, Cys, Cys, Ser, Arg, 1201441, AGT, CCT, CAG, GCT, GTA, AGC, AAG, AGA, CAG, CAC, TGG, CCC, TTG, GCC, AGC, GTC, 1488, 121, Ser, Pro, Gln, Ala, Val, Ser, Lys, Arg, Gln, His, Trp, Pro, Leu, Ala, Ser, Val, 1361489, CTA, CCC, TGC, CCA, ACT, CCA, AGG, ACT, GGG, TAT, GGA, TCG, CTG, GGC, CCT, AGG, 1536, 137, Leu, Pro, Cys, Pro, Thr, Pro, Arg, Thr, Gly, Tyr, Gly, Ser, Leu, Gly, Pro, Arg, 1521537, CTC, TTG, CTT, CTG, GGG, CTA, TTG, GAG, GGT, CAG, TGT, CTG, TGA, CTG, AAT, AAA, 1584, 153, Leu, Leu, Leu, Leu, Gly, Leu, Leu, Glu, Gly, Gln, Cys, Leu, * *, 1651585, GTT, CCA, TTT, TGT, GGT, CCT, GCA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, A, 1630

5.PP6455

A: nucleotide sequence, (SEQ, ID, NO:13), length: 2331bp, 1, GCAAATTATG, GGTGAAATGT, CCCAACTGCC, GGAAGGTGAA, AGTGTTCTGT, GATGTAAAAT, 61, TTAGGTCACA, CTCTATAAAG, CTTCTCCTTA, TTCTATGTGT, GAACAGCTAG, TCTGTATCTT, 121, CACCTATGCA, TATTTAAAAA, TCAACCTTAC, GAAGGCTCTT, GGCCACCATA, ATCCTTCCTA, 181, CCCTGTAGCA, AGAGCCCAGC, CTCAGACTAT, GCTTCCTTCT, GCCTCCGAGT, GCAATGCCTT, 241, CCCCCGAGTC, TCCAAGGTAC, CAAACCGGTC, AGGGGCAGCT, GAGACAGCTC, TACTTGTACG, 301, AGTCCTCCCC, AAGCCCTTGA, AATCACAGGC, ATCTCTGCTG, TCCCTGCCCT, TTATCCACAT, 361, CACTGAACAA, CTAAGCACAC, ACATCTGTGT, AGTTTTATTT, AAAGTGTTCC, ATGTGTGTTT, 421, GTTTACAATT, AACAACATGA, ATGACTGCAG, TATGGATGCA, GCAGAAAGGA, ATGCTGAGGG, 481, AGGACTCCAG, TTGGAATGAG, CCACTTTTCC, AGGACTAGGA, ATGAACTTTC, CCCAGTACCA, 541, ACAAGGCAGC, CTCCAGGGCA, AGAAATGGTA, ACAGAATCCA, TCCTGTTGAC, AGTCAAGATG, 601, GAATTACAGA, GAATTCTCAC, CTCTTTTTTG, ACTCTCAGGT, GGAAACCCCC, TTCCCATGGG, 661, GTGAAGCGCA, GTCTGCTCCA, GAGACCCACT, GTTAGGGTCG, GGGATGTCAC, AGAAATTAAC, 721, AGGGCAGCCA, ATTCCCATCC, AGAGGGGCCC, AGGATGACCC, CGAACCCTCT, AGCTCAGCCC, 781, CAAGCTCGGG, CCAGGGAGTG, AAGCCTTTGT, CCCCAAGCAA, CAGAGTGAGG, GTCTGTCTCT, 841, AACCCGGTGG, GCTCCAGTGA, AAGGAAAATG, GCCTGGAGGT, GCCCACAGGA, GGGCGCCCTA, 901, GTTCTGAGAC, AGGTCTACGG, CTCCCAGACT, GCGTCCCCAT, GAGTAACAGA, GGGACACGCA, 961, GAGGGGCATA, CTGAGTGCCT, ATAGGGGACT, CACAGACTGC, AGATGCACGC, TGCGGATCCA1021, GAAGCCGGTC, AGGTAATGAG, GTGCAGAGGT, GTGGGGAAGA, CCTGGATGCC, TCCCTGGGTG1081, CCAACCAGCC, TAACCAGCCG, GGGCCACCAA, ACAGAAGTGC, TTCTGACATT, AACGCGACAC1141, ACAGAAGGTG, TGTAGGGTGG, GTAGTGGAAG, TGACCGCAGA, GGCCTCTGGG, GATTGTAGTT1201, TTGGAGCTAG, AGAGGCGGGC, AAGCAGTTGG, CTTCGCCCAC, ACGGTGTGCC, TCTCACATCT1261, GCACAGCGCA, CACAACCAAG, CTTAGGAGCC, GACTGTTAAG, ATGCCCCAGT, GACACGGACA1321, AGTTTCTCCT, CTGCAACCCA, ATGAGAGCTG, CTGACCACGA, GAGCATCGCG, GGACCGCCAA1381, AGGATTCTGG, AAAATGTGGT, CCCGGGTGGC, CAGTGTGCGC, TGACCTTCAC, CTGAAGGTGA1441, GCTGAGCTCA, CCATGCAAGT, CTCCACCCTG, GGGTGCCCTT, CCCCAAGCAG, ATGCCAGGTT1501, GGGGCAGAAG, CAGTTCAGGG, AGAAGCGATG, CGCTCCTGGG, ACTGCCGGTT, TGGGGGCAAC1561, ATCGGCCCTG, TGTCCCCTAG, AGTAGGAGGG, TGTACCAGGA, TGGGGAACCC, CAAGGCCGTT1621, TTCAGGGAGA, ACAAGATTGG, CTTGAGGCAA, ACTCCCGGAA, TGGAGATGGG, GAGAGTCTGG1681, TCGCATTTCC, CCAGGAGTTT, AGGGGATGAA, GGCTGGACTT, GGGTGAACAG, CAAAAGATCC1741, CCTGGTGATA, GTGGTGGTGA, GGATCAGAGG, CTTGAGCCAG, AAATTCCCGA, GGTGTTTGTT1801, TGTTTTGTTT, TTTTTGAGAC, AGAGTCTTGA, TCTGTCTCCC, AGGATGTAGT, GCAATGGCAT1861, GCTCTTGGCT, CATTGCAACC, TCCGCCTCCC, AGGTTCAGGC, GATTCTCCTG, CCTCAGCCTC1921, CCAAGTAGCT, GAGATTATAG, GCACCTGCCA, CTGTGCCCAC, CTAAATTTTT, TTTGTTTTTT1981, TGTATTTTTG, GTAGAGACGA, TGTTTCACCA, CATTGCCCAG, CCTGGTCTCG, AACTCCTGAC2041, CTCAAGTGAT, CCACCTGCCT, CGGCCTCCCA, AAGTGCTGGG, ATTACAGGCA, TGAGCCCCCA2101, CACCCAGCTC, ATTTTTATCT, TTTAACTTAA, AGGTTTTTAT, TTTTCTCTAT, TTTTACTCTT2161, ACAGGTACGG, CTTGAAGGAG, ACTTCTGGAG, GGTGGGGTGG, TGTTGAAGAG, AAGGCACAAT2221, TGTCACCATT, TTGTTCAACA, TGGGCGTTTT, CTTTGTGCAT, TGATTTGCAT, TTTTAAAGGT2281, ATTCCATTAA, AAATATGTTT, ATCTAAAAAA, AAAAAAAAAA, AAAAAAAAAA, A

B: aminoacid sequence (SEQ ID NO:14) length: 134 amino acid/11 MCEQLVCIFT YAYLKINLTK ALGHHNPSYP VARAQPQTML PSASECNAFP RVSKVPNRSG 61 AAETALLVRV LPKPLKSQAS LLSLPFIHIT EQLSTHICVV LFKVFHVCLF TINNMNDCSM121 DAAERNAEGG LQLE

C. Nucleotide and amino acid composite sequence (SEQ ID NO:15)

Clone number: PP6455

Start code: 95 ATG stop coding: 497 TGA

protein molecular weight: 14783.53, 1, G, CAA, ATT, ATG, GGT, GAA, ATG, TCC, CAA, CTG, CCG, GAA, GGT, GAA, AGT, GTT, 46, 47, CTG, TGA, TGT, AAA, ATT, TAG, GTC, ACA, CTC, TAT, AAA, GCT, TCT, CCT, TAT, TCT, 94, 95, ATG, TGT, GAA, CAG, CTA, GTC, TGT, ATC, TTC, ACC, TAT, GCA, TAT, TTA, AAA, ATC, 142, 1, Met, Cys, Glu, Gln, Leu, Val, Cys, Ile, Phe, Thr, Tyr, Ala, Tyr, Leu, Lys, Ile, 16, 143, AAC, CTT, ACG, AAG, GCT, CTT, GGC, CAC, CAT, AAT, CCT, TCC, TAC, CCT, GTA, GCA, 190, 17, Asn, Leu, Thr, Lys, Ala, Leu, Gly, His, His, Asn, Pro, Ser, Tyr, Pro, Val, Ala, 32, 191, AGA, GCC, CAG, CCT, CAG, ACT, ATG, CTT, CCT, TCT, GCC, TCC, GAG, TGC, AAT, GCC, 238, 33, Arg, Ala, Gln, Pro, Gln, Thr, Met, Leu, Pro, Ser, Ala, Ser, Glu, Cys, Asn, Ala, 48, 239, TTC, CCC, CGA, GTC, TCC, AAG, GTA, CCA, AAC, CGG, TCA, GGG, GCA, GCT, GAG, ACA, 286, 49, Phe, Pro, Arg, Val, Ser, Lys, Val, Pro, Asn, Arg, Ser, Gly, Ala, Ala, Glu, Thr, 64, 287, GCT, CTA, CTT, GTA, CGA, GTC, CTC, CCC, AAG, CCC, TTG, AAA, TCA, CAG, GCA, TCT, 334, 65, Ala, Leu, Leu, Val, Arg, Val, Leu, Pro, Lys, Pro, Leu, Lys, Ser, Gln, Ala, Ser, 80, 335, CTG, CTG, TCC, CTG, CCC, TTT, ATC, CAC, ATC, ACT, GAA, CAA, CTA, AGC, ACA, CAC, 382, 81, Leu, Leu, Ser, Leu, Pro, Phe, Ile, His, Ile, Thr, Glu, Gln, Leu, Ser, Thr, His, 96, 383, ATC, TGT, GTA, GTT, TTA, TTT, AAA, GTG, TTC, CAT, GTG, TGT, TTG, TTT, ACA, ATT, 430, 97, Ile, Cys, Val, Val, Leu, Phe, Lys, Val, Phe, His, Val, Cys, Leu, Phe, Thr, Ile, 112, 431, AAC, AAC, ATG, AAT, GAC, TGC, AGT, ATG, GAT, GCA, GCA, GAA, AGG, AAT, GCT, GAG, 478, 113, Asn, Asn, Met, Asn, Asp, Cys, Ser, Met, Asp, Ala, Ala, Glu, Arg, Asn, Ala, Glu, 128, 479, GGA, GGA, CTC, CAG, TTG, GAA, TGA, GCC, ACT, TTT, CCA, GGA, CTA, GGA, ATG, AAC, 526, 129, Gly, Gly, Leu, Gln, Leu, Glu, * *, 135, 527, TTT, CCC, CAG, TAC, CAA, CAA, GGC, AGC, CTC, CAG, GGC, AAG, AAA, TGG, TAA, CAG, 574, 575, AAT, CCA, TCC, TGT, TGA, CAG, TCA, AGA, TGG, AAT, TAC, AGA, GAA, TTC, TCA, CCT, 622, 623, CTT, TTT, TGA, CTC, TCA, GGT, GGA, AAC, CCC, CTT, CCC, ATG, GGG, TGA, AGC, GCA, 670, 671, GTC, TGC, TCC, AGA, GAC, CCA, CTG, TTA, GGG, TCG, GGG, ATG, TCA, CAG, AAA, TTA, 718, 719, ACA, GGG, CAG, CCA, ATT, CCC, ATC, CAG, AGG, GGC, CCA, GGA, TGA, CCC, CGA, ACC, 766, 767, CTC, TAG, CTC, AGC, CCC, AAG, CTC, GGG, CCA, GGG, AGT, GAA, GCC, TTT, GTC, CCC, 814, 815, AAG, CAA, CAG, AGT, GAG, GGT, CTG, TCT, CTA, ACC, CGG, TGG, GCT, CCA, GTG, AAA, 862, 863, GGA, AAA, TGG, CCT, GGA, GGT, GCC, CAC, AGG, AGG, GCG, CCC, TAG, TTC, TGA, GAC, 910, 911, AGG, TCT, ACG, GCT, CCC, AGA, CTG, CGT, CCC, CAT, GAG, TAA, CAG, AGG, GAC, ACG, 958, 959, CAG, AGG, GGC, ATA, CTG, AGT, GCC, TAT, AGG, GGA, CTC, ACA, GAC, TGC, AGA, TGC, 10061007, ACG, CTG, CGG, ATC, CAG, AAG, CCG, GTC, AGG, TAA, TGA, GGT, GCA, GAG, GTG, TGG, 10541055, GGA, AGA, CCT, GGA, TGC, CTC, CCT, GGG, TGC, CAA, CCA, GCC, TAA, CCA, GCC, GGG, 11021103, GCC, ACC, AAA, CAG, AAG, TGC, TTC, TGA, CAT, TAA, CGC, GAC, ACA, CAG, AAG, GTG, 11501151, TGT, AGG, GTG, GGT, AGT, GGA, AGT, GAC, CGC, AGA, GGC, CTC, TGG, GGA, TTG, TAG, 11981199, TTT, TGG, AGC, TAG, AGA, GGC, GGG, CAA, GCA, GTT, GGC, TTC, GCC, CAC, ACG, GTG, 12461247, TGC, CTC, TCA, CAT, CTG, CAC, AGC, GCA, CAC, AAC, CAA, GCT, TAG, GAG, CCG, ACT, 12941295, GTT, AAG, ATG, CCC, CAG, TGA, CAC, GGA, CAA, GTT, TCT, CCT, CTG, CAA, CCC, AAT, 13421343, GAG, AGC, TGC, TGA, CCA, CGA, GAG, CAT, CGC, GGG, ACC, GCC, AAA, GGA, TTC, TGG, 13901391, AAA, ATG, TGG, TCC, CGG, GTG, GCC, AGT, GTG, CGC, TGA, CCT, TCA, CCT, GAA, GGT, 14381439, GAG, CTG, AGC, TCA, CCA, TGC, AAG, TCT, CCA, CCC, TGG, GGT, GCC, CTT, CCC, CAA, 14861487, GCA, GAT, GCC, AGG, TTG, GGG, CAG, AAG, CAG, TTC, AGG, GAG, AAG, CGA, TGC, GCT, 15341535, CCT, GGG, ACT, GCC, GGT, TTG, GGG, GCA, ACA, TCG, GCC, CTG, TGT, CCC, CTA, GAG, 15821583, TAG, GAG, GGT, GTA, CCA, GGA, TGG, GGA, ACC, CCA, AGG, CCG, TTT, TCA, GGG, AGA, 16301631, ACA, AGA, TTG, GCT, TGA, GGC, AAA, CTC, CCG, GAA, TGG, AGA, TGG, GGA, GAG, TCT, 16781679, GGT, CGC, ATT, TCC, CCA, GGA, GTT, TAG, GGG, ATG, AAG, GCT, GGA, CTT, GGG, TGA, 17261727, ACA, GCA, AAA, GAT, CCC, CTG, GTG, ATA, GTG, GTG, GTG, AGG, ATC, AGA, GGC, TTG, 17741775, AGC, CAG, AAA, TTC, CCG, AGG, TGT, TTG, TTT, GTT, TTG, TTT, TTT, TTG, AGA, CAG, 18221823, AGT, CTT, GAT, CTG, TCT, CCC, AGG, ATG, TAG, TGC, AAT, GGC, ATG, CTC, TTG, GCT, 18701871, CAT, TGC, AAC, CTC, CGC, CTC, CCA, GGT, TCA, GGC, GAT, TCT, CCT, GCC, TCA, GCC, 19181919, TCC, CAA, GTA, GCT, GAG, ATT, ATA, GGC, ACC, TGC, CAC, TGT, GCC, CAC, CTA, AAT, 19661967, TTT, TTT, TGT, TTT, TTT, GTA, TTT, TTG, GTA, GAG, ACG, ATG, TTT, CAC, CAC, ATT, 20142015, GCC, CAG, CCT, GGT, CTC, GAA, CTC, CTG, ACC, TCA, AGT, GAT, CCA, CCT, GCC, TCG, 20622063, GCC, TCC, CAA, AGT, GCT, GGG, ATT, ACA, GGC, ATG, AGC, CCC, CAC, ACC, CAG, CTC, 21102111, ATT, TTT, ATC, TTT, TAA, CTT, AAA, GGT, TTT, TAT, TTT, TCT, CTA, TTT, TTA, CTC, 21582159, TTA, CAG, GTA, CGG, CTT, GAA, GGA, GAC, TTC, TGG, AGG, GTG, GGG, TGG, TGT, TGA, 22062207, AGA, GAA, GGC, ACA, ATT, GTC, ACC, ATT, TTG, TTC, AAC, ATG, GGC, GTT, TTC, TTT, 22542255, GTG, CAT, TGA, TTT, GCA, TTT, TTA, AAG, GTA, TTC, CAT, TAA, AAA, TAT, GTT, TAT, 23022303, CTA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AAA, AA, 2331

6.PP6489

A: nucleotide sequence, (SEQ, ID, NO:16) length: 2571bp, 1, GGTGATGTGG, GGGTGGCCCA, TGATGTGGGA, ATGGGGGCCT, GGCCGGTACC, GACATCTCCA, 61, GCCAGAGCTC, AGGGTTGCCT, CTGCCATCAT, CACCTCGGCC, ACATCCCCTT, TCCTTCTGAT, 121, CCCAGACACA, TTGGGCTCTG, TCTTGCCTGC, TGTTCTGTCT, GCCTGGAAAG, CTAATGTTGT, 181, TGGTGCCAAA, TTCCTGAAGA, GTCCTCCCTG, ATGGCCCGTC, CACCACGCGA, AGCTGTGGAA, 241, ATTGCCCGCT, GCTGGGAGGA, ACAGTGCCGC, CCGGCCGAGT, CCTGCGCGTG, TGTGGAAGCG, 301, GAGGCCAAGG, GTTGGTATTC, GTAAGGTCTG, GGAGTTTGGT, TTAAGGCAGA, TCTTTCAATG, 361, TGGGTGGCTG, GTCTGATTTG, GACTGGGACA, TGTTTACAAT, GTGTAATAAG, ACTTTAAGAT, 421, CAGTGGACGC, AGCAGAGGGC, GTGAAGCCAG, CCTGATGGTG, GTTTGCTGAG, GGAGCAGCTT, 481, GCCCAGGAGA, GTGGCTTGTT, GTTCTTAGAA, GGACTCCCTG, GGTGAGCAGG, TCAAACAACT, 541, TTCAGGAGCT, CTGATCAGTC, AAGTTGCATG, CTGTTTTGCC, CTCTTGGGTG, GAAATTTGCT, 601, GCAGTAGTCC, AGTTAAAGTG, TACTTGTGCA, TTTCTGACAC, CTCACCCTTC, AGGTCCAACT, 661, TAGCCTCCTC, ACCAGGCCAG, CTTGTCTCCT, GTAGTTCTCT, TGGCACCCTG, TGTGTTCCTA, 721, CTCAGGACTT, GTCACAGTGT, GTCATCACAC, ACACGCAAGC, ACATGCTGTG, GGACATTGAT, 781, GTCTTGCCCA, CTGGAAGGGT, TCCGTAGGGT, GGAGTCAGCC, CCATTTTGCT, CTGCTGGCAC, 841, TTAGCACGGC, ATGTGGCACG, TAGCAAGTAG, TTAGGAAATG, TTTGCAGAGG, AACATGAATA, 901, AGTCTTGCAC, GAGGTGCCGG, GGAGCTCAGA, GGAGGAAGCA, GCCTCCTTTT, TTTCCAGGAG, 961, ACCAGGGGAC, GCTTTACCCA, GAAGGGCCCT, GCTGCTGTGG, AGGGTGCAGC, CTCCTTGGGG1021, GCTGAGTGTG, GAGGGCAAGC, GGAGGGTAGG, GCTCAGGGGC, CAGGGTGATG, GGTGCGGGTG1081, GGAGGTGGAT, CAGACAGCAT, TGTGAGGGTA, AAGGGTTGGG, ATTTTAAGCA, AAAGGCAGCA1141, AAGAGCTGTT, GAAGGCTTTT, TGGCAGAGGC, ATGTCAAGAC, CAGATTTGGA, GTTTCGAGAT1201, ACTCATGTAG, CTATACCATG, GGGGTGGGTG, AAAGCGTGGG, TGGGAGAAGG, CACAGGGGCT1261, GGAGAGGAAT, GGGAGGGAAG, GCGTTGTGGT, CACTGCTTCC, TGGCAGGGGC, GGGGAGGGAG1321, CCTCAACTGG, GTCTGTGGGG, CAGAGGAGCC, AGCACCACTC, CAGGGCTCGT, CCCGGGTGGG1381, TGTGGATGGA, GATCGCCACA, GCCTGCGTGG, CTCCCAGGGT, GAGGGTCAGG, CTCACAGGGA1441, GGACACCAGG, CCTCTTATCG, TGGCTCCATT, CTCTGTGGAC, TGCCCTTGGT, GGGACTAAGA1501, GCAGGCAGGT, CTCCATGTGT, CCTGGACACG, GCTCCTGACC, CAGCACGTGT, GTCCACTTTT1561, GGGCTGTGGT, GAGGGTGATT, GAGGGGCAGT, GTGCCAATGT, AGAATGACTA, TATGGCATGT1621, TTGTGGGCTA, AAGTAAGTGA, ATGCTTAAAT, TGACACTAAG, ATGCGGTGAG, CTTGATCGTG1681, GGTCGGCCGG, TTTCCATTCA, GCTAAAATTC, GTGAAGTGGG, GGCATCACTG, ACTTTTTTTG1741, TAAAGAGAAA, ATAACCTGTA, AATAGGCTTT, TAAAAATAGA, CACTTACTCT, TGCTTTTTTT1801, GTAAATCAGA, TTGACCTGTC, AGTGCACTCT, GGGGTCCGGC, CAGCTGCGAT, GATCTTTAGA1861, CCAGTCAGCC, GCCGGCTGAG, CTGACACCTT, TTAGATGGAA, ATGGAATAAA, TGCTGCACCA1921, CATTGTTCGT, GTGGGTGGTG, AATGCAGGTG, TTTGAAACCA, TTAGCTTCTT, TGCATAATTA1981, AAAACCTTAA, TTTTTTGTGA, AATCTTTAAT, CATAGAAGAA, ATGCTTCTTT, CCAGTTTGAG2041, TGTTTCTCTT, AATATTACCA, TTGCTTTAAG, ACAATTACCT, TCAGGGCTCA, TTACTTTCCT2101, GGACAGTTTA, CAGGCCAGAG, TGGTCTCCAC, TCAGCCACTA, GATCTTAGAG, GATTCTAAGA2161, AACCCTATTC, GTTAAGCCAG, GTAACTCATA, TATTCTGAAT, CTATAAACAT, GTCTGAAAAT2221, TGTGAAACAT, ACTGTAGAGT, TTATAGAAGT, TCTTAAAATA, CATACATTGT, GCCGGGTACG2281, GTGGCTCATG, CCTGTAATCC, CAGCACTTTG, GGAAGCCAAG, GTGGGCGGAT, CATGAGGTTA2341, GGAGTTTGAG, ACCAGCCTGG, CCAACATGGT, GGAAACATGT, CTCTAATAAA, AATACAAAAA2401, TTAGCCGGGC, GTAGTGGTGG, GTGCCTGTAA, TCCCAGCTAC, TCAGGAGGCG, GAGGCAGGAG2461, GATCGCTGGA, ATCCGGGAGG, CAGAGGTTGC, AGTGAGCGGA, GATCAAGCCA, TTGCATTCCA2521, GCCTGGGCGA, TAGAGCGAGA, CTCCATGTTA, AAAAAAAAAA, AAAAAAAAAA, A

B: aminoacid sequence (SEQ ID NO:17) length: 106 amino acid/11 MGVGESVGGR RHRGWRGMGG KALWSLLPGR GGEGASTGSV GQRSQHHSRA RPGWVWMEIA61 TACVAPRVRV RLTGRTPGLL SWLHSLWTAL GGTKSRQVSM CPGHGS

C. Nucleotide and amino acid composite sequence (SEQ ID NO:18)

Clone number: PP6489

Start code: 1218 ATG stop coding: 1536 TGA

protein molecular weight: 11280.36, 1, GG, TGA, TGT, GGG, GGT, GGC, CCA, TGA, TGT, GGG, AAT, GGG, GGC, CTG, GCC, GGT, 47, 48, ACC, GAC, ATC, TCC, AGC, CAG, AGC, TCA, GGG, TTG, CCT, CTG, CCA, TCA, TCA, CCT, 95, 96, CGG, CCA, CAT, CCC, CTT, TCC, TTC, TGA, TCC, CAG, ACA, CAT, TGG, GCT, CTG, TCT, 143, 144, TGC, CTG, CTG, TTC, TGT, CTG, CCT, GGA, AAG, CTA, ATG, TTG, TTG, GTG, CCA, AAT, 191, 192, TCC, TGA, AGA, GTC, CTC, CCT, GAT, GGC, CCG, TCC, ACC, ACG, CGA, AGC, TGT, GGA, 239, 240, AAT, TGC, CCG, CTG, CTG, GGA, GGA, ACA, GTG, CCG, CCC, GGC, CGA, GTC, CTG, CGC, 287, 288, GTG, TGT, GGA, AGC, GGA, GGC, CAA, GGG, TTG, GTA, TTC, GTA, AGG, TCT, GGG, AGT, 335, 336, TTG, GTT, TAA, GGC, AGA, TCT, TTC, AAT, GTG, GGT, GGC, TGG, TCT, GAT, TTG, GAC, 383, 384, TGG, GAC, ATG, TTT, ACA, ATG, TGT, AAT, AAG, ACT, TTA, AGA, TCA, GTG, GAC, GCA, 431, 432, GCA, GAG, GGC, GTG, AAG, CCA, GCC, TGA, TGG, TGG, TTT, GCT, GAG, GGA, GCA, GCT, 479, 480, TGC, CCA, GGA, GAG, TGG, CTT, GTT, GTT, CTT, AGA, AGG, ACT, CCC, TGG, GTG, AGC, 527, 528, AGG, TCA, AAC, AAC, TTT, CAG, GAG, CTC, TGA, TCA, GTC, AAG, TTG, CAT, GCT, GTT, 575, 576, TTG, CCC, TCT, TGG, GTG, GAA, ATT, TGC, TGC, AGT, AGT, CCA, GTT, AAA, GTG, TAC, 623, 624, TTG, TGC, ATT, TCT, GAC, ACC, TCA, CCC, TTC, AGG, TCC, AAC, TTA, GCC, TCC, TCA, 671, 672, CCA, GGC, CAG, CTT, GTC, TCC, TGT, AGT, TCT, CTT, GGC, ACC, CTG, TGT, GTT, CCT, 719, 720, ACT, CAG, GAC, TTG, TCA, CAG, TGT, GTC, ATC, ACA, CAC, ACG, CAA, GCA, CAT, GCT, 767, 768, GTG, GGA, CAT, TGA, TGT, CTT, GCC, CAC, TGG, AAG, GGT, TCC, GTA, GGG, TGG, AGT, 815, 816, CAG, CCC, CAT, TTT, GCT, CTG, CTG, GCA, CTT, AGC, ACG, GCA, TGT, GGC, ACG, TAG, 863, 864, CAA, GTA, GTT, AGG, AAA, TGT, TTG, CAG, AGG, AAC, ATG, AAT, AAG, TCT, TGC, ACG, 911, 912, AGG, TGC, CGG, GGA, GCT, CAG, AGG, AGG, AAG, CAG, CCT, CCT, TTT, TTT, CCA, GGA, 959, 960, GAC, CAG, GGG, ACG, CTT, TAC, CCA, GAA, GGG, CCC, TGC, TGC, TGT, GGA, GGG, TGC, 10071008, AGC, CTC, CTT, GGG, GGC, TGA, GTG, TGG, AGG, GCA, AGC, GGA, GGG, TAG, GGC, TCA, 10551056, GGG, GCC, AGG, GTG, ATG, GGT, GCG, GGT, GGG, AGG, TGG, ATC, AGA, CAG, CAT, TGT, 11031104, GAG, GGT, AAA, GGG, TTG, GGA, TTT, TAA, GCA, AAA, GGC, AGC, AAA, GAG, CTG, TTG, 11511152, AAG, GCT, TTT, TGG, CAG, AGG, CAT, GTC, AAG, ACC, AGA, TTT, GGA, GTT, TCG, AGA, 11991200, TAC, TCA, TGT, AGC, TAT, ACC, ATG, GGG, GTG, GGT, GAA, AGC, GTG, GGT, GGG, AGA, 1247, 1, Met, Gly, Val, Gly, Glu, Ser, Val, Gly, Gly, Arg, 101248, AGG, CAC, AGG, GGC, TGG, AGA, GGA, ATG, GGA, GGG, AAG, GCG, TTG, TGG, TCA, CTG, 1295, 11, Arg, His, Arg, Gly, Trp, Arg, Gly, Met, Gly, Gly, Lys, Ala, Leu, Trp, Ser, Leu, 261296, CTT, CCT, GGC, AGG, GGC, GGG, GAG, GGA, GCC, TCA, ACT, GGG, TCT, GTG, GGG, CAG, 1343, 27, Leu, Pro, Gly, Arg, Gly, Gly, Glu, Gly, Ala, Ser, Thr, Gly, Ser, Val, Gly, Gln, 421344, AGG, AGC, CAG, CAC, CAC, TCC, AGG, GCT, CGT, CCC, GGG, TGG, GTG, TGG, ATG, GAG, 1391, 43, Arg, Ser, Gln, His, His, Ser, Arg, Ala, Arg, Pro, Gly, Trp, Val, Trp, Met, Glu, 581392, ATC, GCC, ACA, GCC, TGC, GTG, GCT, CCC, AGG, GTG, AGG, GTC, AGG, CTC, ACA, GGG, 1439, 59, Ile, Ala, Thr, Ala, Cys, Val, Ala, Pro, Arg, Val, Arg, Val, Arg, Leu, Thr, Gly, 741440, AGG, ACA, CCA, GGC, CTC, TTA, TCG, TGG, CTC, CAT, TCT, CTG, TGG, ACT, GCC, CTT, 1487, 75, Arg, Thr, Pro, Gly, Leu, Leu, Ser, Trp, Leu, His, Ser, Leu, Trp, Thr, Ala, Leu, 901488, GGT, GGG, ACT, AAG, AGC, AGG, CAG, GTC, TCC, ATG, TGT, CCT, GGA, CAC, GGC, TCC, 1535, 91, Gly, Gly, Thr, Lys, Ser, Arg, Gln, Val, Ser, Met, Cys, Pro, Gly, His, Gly, Ser, 1061536, TGA, CCC, AGC, ACG, TGT, GTC, CAC, TTT, TGG, GCT, GTG, GTG, AGG, GTG, ATT, GAG, 1583, 107, * *, 1071584, GGG, CAG, TGT, GCC, AAT, GTA, GAA, TGA, CTA, TAT, GGC, ATG, TTT, GTG, GGC, TAA, 16311632, AGT, AAG, TGA, ATG, CTT, AAA, TTG, ACA, CTA, AGA, TGC, GGT, GAG, CTT, GAT, CGT, 16791680, GGG, TCG, GCC, GGT, TTC, CAT, TCA, GCT, AAA, ATT, CGT, GAA, GTG, GGG, GCA, TCA, 17271728, CTG, ACT, TTT, TTT, GTA, AAG, AGA, AAA, TAA, CCT, GTA, AAT, AGG, CTT, TTA, AAA, 17751776, ATA, GAC, ACT, TAC, TCT, TGC, TTT, TTT, TGT, AAA, TCA, GAT, TGA, CCT, GTC, AGT, 18231824, GCA, CTC, TGG, GGT, CCG, GCC, AGC, TGC, GAT, GAT, CTT, TAG, ACC, AGT, CAG, CCG, 18711872, CCG, GCT, GAG, CTG, ACA, CCT, TTT, AGA, TGG, AAA, TGG, AAT, AAA, TGC, TGC, ACC, 19191920, ACA, TTG, TTC, GTG, TGG, GTG, GTG, AAT, GCA, GGT, GTT, TGA, AAC, CAT, TAG, CTT, 19671968, CTT, TGC, ATA, ATT, AAA, AAC, CTT, AAT, TTT, TTG, TGA, AAT, CTT, TAA, TCA, TAG, 20152016, AAG, AAA, TGC, TTC, TTT, CCA, GTT, TGA, GTG, TTT, CTC, TTA, ATA, TTA, CCA, TTG, 20632064, CTT, TAA, GAC, AAT, TAC, CTT, CAG, GGC, TCA, TTA, CTT, TCC, TGG, ACA, GTT, TAC, 21112112, AGG, CCA, GAG, TGG, TCT, CCA, CTC, AGC, CAC, TAG, ATC, TTA, GAG, GAT, TCT, AAG, 21592160, AAA, CCC, TAT, TCG, TTA, AGC, CAG, GTA, ACT, CAT, ATA, TTC, TGA, ATC, TAT, AAA, 22072208, CAT, GTC, TGA, AAA, TTG, TGA, AAC, ATA, CTG, TAG, AGT, TTA, TAG, AAG, TTC, TTA, 22552256, AAA, TAC, ATA, CAT, TGT, GCC, GGG, TAC, GGT, GGC, TCA, TGC, CTG, TAA, TCC, CAG, 23032304, CAC, TTT, GGG, AAG, CCA, AGG, TGG, GCG, GAT, CAT, GAG, GTT, AGG, AGT, TTG, AGA, 23512352, CCA, GCC, TGG, CCA, ACA, TGG, TGG, AAA, CAT, GTC, TCT, AAT, AAA, AAT, ACA, AAA, 23992400, ATT, AGC, CGG, GCG, TAG, TGG, TGG, GTG, CCT, GTA, ATC, CCA, GCT, ACT, CAG, GAG, 24472448, GCG, GAG, GCA, GGA, GGA, TCG, CTG, GAA, TCC, GGG, AGG, CAG, AGG, TTG, CAG, TGA, 24952496, GCG, GAG, ATC, AAG, CCA, TTG, CAT, TCC, AGC, CTG, GGC, GAT, AGA, GCG, AGA, CTC, 25432544, CAT, GTT, AAA, AAA, AAA, AAA, AAA, AAA, AAA, A, 2571

7.PP6614

A: nucleotide sequence, (SEQ, ID, NO:19), length: 3096bp, 1, GATTCGCTAC, CGCCTGGGCA, CCATCCGCCC, ATCTTCCTCG, GTCATGAACA, TGCATGAAAT, 61, TTATGTAAGT, CCATCCTTCC, CCACAATGCT, GCCATCTCCC, CATGGCTCAG, AACCTCAGGG121, ATGCTGGCCC, TGTGCCCTGC, TCCTCCAAGG, GCCTGGACCA, TCCCCTACTA, CAAGGCTGTG, 181, TGTCCCTGGA, CAAGTTACTC, CCCTTCTCTG, GGCCTCTGTT, CCCTGCTTCC, ACAGGATGTG, 241, CTGTGCTGGA, AGAACTGATG, CTCAGATTGA, ATTTCGTGGT, CTTGGCATCA, GCTCCCCCCT, 301, GATCTCTCCA, GCCTGGGAAA, AATGCTGTTG, GTCTCAGTAC, AGCTGGGTTA, GGGCCCAAGG, 361, GGACAGGGGG, TCACCTTGGT, ATTTTGGGAA, GGGAAGGACA, CACACTCCTC, CAGTTCTGGC, 421, CAGAGGGCAG, CAGTTCTCGG, AAATAAATGC, CGGTTCAGCG, GAACCCCAAG, GGAGGAGAGG, 481, GCTTCTCCCT, TCCCACCAGT, GGGACCCTCT, GGGAGAGGAA, TGAAAACCAG, GCCCAAAGTG, 541, AAAGGGTGAG, GAAGGGGAGC, TTCAGCAGGC, CTGGACCGGG, ACATGTGCCG, GAGCATTTGT, 601, CCATCAGTGG, CAGGCAGCGG, GGAGGCAGGG, GCTGGCAGGA, GTGGCCCTCC, CTGCGGAGAC, 661, TTCGGCCTTG, GGTGACCAGA, CCCTGGCCCT, GCCCTTATTC, CCCTGGGCCT, CTGGCTATTT, 721, TCTGCCTCTT, GCTGTTTGTG, TTGGCAGACT, GCCTGGTCAC, GGGACCCTAC, TGCCTCTTCC, 781, CTCCCCTGAG, GGAAAGCTAA, GGCCTGAAGA, AAGCTAAGGC, CGATCAGAAG, GTGCAGAGGA, 841, AAGAGGCAGG, GGTTGAGAAT, GGAAAGCTGA, GGGACCTGGC, CTGGCCACTT, CTCTGTGCCT, 901, GGCCTCAGCT, GCCTCATCTG, GGAAGCAGGA, CTAGTCACCA, CCGCCACCCC, GCCCCGCCCC, 961, ACCACCTGAT, ACCTGGGAGG, CACTAAATGG, TGCTTGGTTC, TTCAACACAA, GTCAAAATTG1021, GAGGCAGCTG, GAATCCTGCA, GCAGCAGGAG, GGCTCAAGAT, TAAACTGCAG, AAGGCCCTGG1081, ACTTGGTGGC, CCTCCAGTGC, CAATGGGCAC, CTGAGGGGCA, GGCCAGGGCA, GAGCAGGAGG1141, CAGACAGGGC, AACCTTTATC, TTGCAGACAG, TGCTGAACCC, AGGGGAGGTG, CTTCCCACAG1201, CCTTCGAGGC, CTCTGAGAAG, TGGCCCAACC, TGATTCATGA, GCCTCTTGAC, CAAGGCAACT1261, GTGCAGGCTC, CTGGGCCTTC, TCCACAGCAG, CTGTGGCATC, CGATCGTGTC, TCAATCCATT1321, CTCTGGGACA, CATGACGCCT, GTCCTGTCGC, CCCAGAACCT, GCTGTCTTGT, GACACCCACC1381, AGCAGCAGGG, CTGCCGCGGT, GGGCGTCTCG, ATGGTGCCTG, GTGGTTCCTG, CGTCGCCGAG1441, GGTATGCAGC, AACAGGGGAT, GTGGGCAGAG, AAGAGGGCAA, GGAGCTCCGT, GGGCATGGCC1501, TGGGCCATGA, TGCACTGAGT, CTTTCTGCCT, TTGCTCCCTC, TTGCTGCCTT, TGCAGGGTGG1561, TGTCTGACCA, CTGCTACCCC, TTCTCGGGCC, GTGAACGAGA, CGAGGCTGGC, CCTGCGCCCC1621, CCTGTATGAT, GCACAGCCGA, GCCATGGGTC, GGGGCAAGCG, CCAGGCCACT, GCCCACTGCC1681, CCAACAGCTA, TGTTTATAAC, AATGACATCT, ACCAGGTCAC, TCCTGTCTAC, CGCCTCGGCT1741, CCAACGACAA, GGAGATCATG, AAGGAGCTGA, TGGAGAATGG, CCCTGTCCAA, GGTAAACCCC1801, CTTATCCAGC, ACCCTGGTTC, CAGAAGCTTG, TGCCTGCTTG, AGAGTGGGCA, CAGTAGCACA1861, AGTGGCCTGC, ACAGCATTCA, GCAGCATGTC, CAGTAGGGCC, AGGAGTAGGG, GTCCCCCCCT1921, CCCACAGGCA, GCACCTGGAG, GGAGCACTTA, GAGCTTTGGT, ATGGAGGGAC, CCTGGTGCCT1981, GGGCACATCT, CAATAGACTC, AGGCTCCAGT, GCCTGTGCCA, ACGGGCTGAG, TGGACCCTAC2041, CTTGACATCT, GCCCACAGCC, CTCATGGAGG, TGCATGAGGA, CTTCTTCCTA, TACAAGGGAG2101, GCATCTACAG, CCACACGCCA, GTGAGCCTTG, GGAGGCCAGA, GAGATACCGC, CGGCATGGGA2161, CCCACTCAGT, CAAGATCACA, GGATGGGGAG, AGGAGACGCT, GCCAGATGGA, AGGACGCTCA2221, AATACTGGAC, TGCGGCCAAC, TCCTGGGGCC, CAGCCTGGGG, CGAGAGGGGC, CACTTCCGCA2281, TCGTGCGCGG, CGTCAATGAG, TGCGACATCG, AGAGCTTCGT, GCTGGGCGTC, TGGGGCCGCG2341, TGGGCATGGA, GGACATGGGT, CATCACTGAG, GCTGCGGGCA, CCACGCGGGG, TCCGGCCTGG2401, GATCCAGGCT, AAGGGCCGGC, GGAAGAGGCC, CCAATGGGGC, GGTGACCCCA, GCCTCGCCCG2461, ACAGAGCCCG, GGGCGCAGGC, GGGCGCCAGG, GCGCTAATCC, CGGCGCGGGT, TCCGCTGACG2521, CAGCGCCCCG, CCTGGGAGCC, GCGGGCAGGC, GAGACTGGCG, GAGCCCCCAG, ACCTCCCAGT2581, GGGGACGGGG, CAGGGCCTGG, CCTGGGAAGA, GCACAGCTGC, AGATCCCAGG, CCCTCTGGCGC2641, CCCCACTCAA, GACTACCAAA, GCCAGGACAC, CTCAAGTCTC, CAGCCCCACT, ACCCCACCCC2701, ACTCCTGTAT, TCTTTTTTTT, TTTTTTTTAG, ACAGGGTCTT, GCTCCGTTGC, CCAGGTTGGA2761, GTGCAGTGGC, CCATCAGGGC, TCACTGTAAC, CTCCGACTCC, TGGGTTCAAG, TGACCCTCCC2821, ACCTCAGCCT, CTCAAGTAGC, TGGGACTACA, GGTGCACCAC, CACACCTGGC, TAATTTTTGT2881, ATTTTTTGTA, AAGAGGGGGG, TCTCACTGTG, TTGCCCAGGC, TGGTCTCGAA, CTCCTGGGCT2941, CAAGCGGTCC, ACCTGCCTCC, GCCTCCCAAA, GTGCTGGGAT, TGCAGGCATG, AGCCACTGCA3001, CCCAGCCCTG, TATTCTTATT, CTTCAGATAT, TTATTTTTCT, TTTCACTGTT, TTAAAATAAA3061, ACCAAAGTAT, TGATAAAAAA, AAAAAAAAAA, AAAAAA

B: amino acid sequence (SEQ ID NO:20) length: 284 amino acid/11 MVLGSSTQVK IGGSWNPAAA GGLKIKLQKA LDLVALQCQW APEGQARAEQ EADRATFILQ 61 TVLNPGEVLP TAFEASEKWP NLIHEPLDQG NCAGSWAFST AAVASDRVSI HSLGHMTPVL121 SPQNLLSCDT HQQQGCRGGR LDGAWWFLRR RGYAATGDVG REEGKELRGH GLGHDALSLS181 AFAPSCCLCR VVSDHCYPFS GRERDEAGPA PPCMMHSRAM GRGKRQATAH CPNSYVYNND241 IYQVTPVYRL GSNDKEIMKE LMENGPVQGK PPYPAPWFQK LVPA

C. Nucleotide and amino acid composite sequence (SEQ ID NO:21)

Clone number: PP6614 plays coding: 987 ATG stop coding: 1839 TGA

Protein Weight: 30892.43 1 GA TTC GCT ACC GCC TGG GCA CCA TCC GCC CAT CTT CCT CGG TCA TGA 47 48 ACA TGC ATG AAA TTT ATG TAA GTC CAT CCT TCC CCA CAA TGC TGC CAT 95 96 CTC CCC ATG GCT CAG AAC CTC AGG GAT GCT GGC CCT GTG CCC TGC TCC 143 144 TCC AAG GGC CTG GAC CAT CCC CTA CTA CAA GGC TGT GTG TCC CTG GAC 191 192 AAG TTA CTC CCC TTC TCT GGG CCT CTG TTC CCT GCT TCC ACA GGA TGT 239 240 GCT GTG CTG GAA GAA CTG ATG CTC AGA TTG AAT TTC GTG GTC TTG GCA 287 288 TCA GCT CCC CCC TGA TCT CTC CAG CCT GGG AAA AAT GCT GTT GGT CTC 335 336 AGT ACA GCT GGG TTA GGG CCC AAG GGG ACA GGG GGT CAC CTT GGT ATT 383 384 TTG GGA AGG GAA GGA CAC ACA CTC CTC CAG TTC TGG CCA GAG GGC AGC 431 432 AGT TCT CGG AAA TAA ATG CCG GTT CAG CGG AAC CCC AAG GGA GGA GAG 479 480 GGC TTC TCC CTT CCC ACC AGT GGG ACC CTC TGG GAG AGG AAT GAA AAC 527 528 CAG GCC CAA AGT GAA AGG GTG AGG AAG GGG AGC TTC AGC AGG CCT GGA 575 576 CCG GGA CAT GTG CCG GAG CAT TTG TCC ATC AGT GGC AGG CAG CGG GGA 623 624 GGC AGG GGC TGG CAG GAG TGG CCC TCC CTG CGG AGA CTT CGG CCT TGG 671 672 GTG ACC AGA CCC TGG CCC TGC CCT TAT TCC CCT GGG CCT CTG GCT ATT 719 720 TTC TGC CTC TTG CTG TTT GTG TTG GCA GAC TGC CTG GTC ACG GGA CCC 767 768 TAC TGC CTC TTC CCT CCC CTG AGG GAA AGC TAA GGC CTG AAG AAA GCT 815 816 AAG GCC GAT CAG AAG GTG CAG AGG AAA GAG GCA GGG GTT GAG AAT GGA 863 864 AAG CTG AGG GAC CTG GCC TGG CCA CTT CTC TGT GCC TGG CCT CAG CTG 911 912 CCT CAT CTG GGA AGC AGG ACT AGT CAC CAC CGC CAC CCC GCC CCG CCC 959 960 CAC CAC CTG ATA CCT GGG AGG CAC TAA ATG GTG CTT GGT TCT TCA ACA 1007 1 Met Val Leu Gly Ser Ser Thr 7 1008 CAA GTC AAA ATT GGA GGC AGC TGG AAT CCT GCA GCA GCA GGA GGG CTC 1055 8 Gln Val Lys Ile Gly Gly Ser Trp Asn Pro Ala Ala Ala Gly Gly Leu 23 1056 AAG ATT AAA CTG CAG AAG GCC CTG GAC TTG GTG GCC CTC CAG TGC CAA 1103 24 Lys Ile Lys Leu Gln Lys Ala Leu Asp Leu Val Ala Leu Gln Cys Gln 39 1104 TGG GCA CCT GAG GGG CAG GCC AGG GCA GAG CAG GAG GCA GAC AGG GCA 1151 40 Trp Ala Pro Glu Gly Gln Ala Arg Ala Glu Gln Glu Ala Asp Arg Ala 55 1152 ACC TTT ATC TTG CAG ACA GTG CTG AAC CCA GGG GAG GTG CTT CCC ACA 1199 56 Thr Phe Ile Leu Gln Thr Val Leu Asn Pro Gly Glu Val Leu Pro Thr 71 1200 GCC TTC GAG GCC TCT GAG AAG TGG CCC AAC CTG ATT CAT GAG CCT CTT 1247 72 Ala Phe Glu Ala Ser Glu Lys Trp Pro Asn Leu Ile His Glu Pro Leu 87 1248 GAC CAA GGC AAC TGT GCA GGC TCC TGG GCC TTC TCC ACA GCA GCT GTG 1295 88 Asp Gln Gly Asn Cys Ala Gly Ser Trp Ala Phe Ser Thr Ala Ala Val 103 1296 GCA TCC GAT CGT GTC TCA ATC CAT TCT CTG GGA CAC ATG ACG CCT GTC 1343 104 Ala Ser Asp Arg Val Ser Ile His Ser Leu Gly His Met Thr Pro Val 119 1344 CTG TCG CCC CAG AAC CTG CTG TCT TGT GAC ACC CAC CAG CAG CAG GGC 1391 120 Leu Ser Pro Gln Asn Leu Leu Ser Cys Asp Thr His Gln Gln Gln Gly 135 1392 TGC CGC GGT GGG CGT CTC GAT GGT GCC TGG TGG TTC CTG CGT CGC CGA 1439 136 Cys Arg Gly Gly Arg Leu Asp Gly Ala Trp Trp Phe Leu Arg Arg Arg 151 1440 GGG TAT GCA GCA ACA GGG GAT GTG GGC AGA GAA GAG GGC AAG GAG CTC 1487 152 Gly Tyr Ala Ala Thr Gly Asp Val Gly Arg Glu Glu Gly Lys Glu Leu 167 1488 CGT GGG CAT GGC CTG GGC CAT GAT GCA CTG AGT CTT TCT GCC TTT GCT 1535 168 Arg Gly His Gly Leu Gly His Asp Ala Leu Ser Leu Ser Ala Phe Ala 183 1536 CCC TCT TGC TGC CTT TGC AGG GTG GTG TCT GAC CAC TGC TAC CCC TTC 1583 184 Pro Ser Cys Cys Leu Cys Arg Val Val Ser Asp His Cys Tyr Pro Phe 199 1584 TCG GGC CGT GAA CGA GAC GAG GCT GGC CCT GCG CCC CCC TGT ATG ATG 1631 200 Ser Gly Arg Glu Arg Asp Glu Ala Gly Pro Ala Pro Pro Cys Met Met 215 1632 CAC AGC CGA GCC ATG GGT CGG GGC AAG CGC CAG GCC ACT GCC CAC TGC 1679 216 His Ser Arg Ala Met Gly Arg Gly Lys Arg Gln Ala Thr Ala His Cys 231 1680 CCC AAC AGC TAT GTT TAT AAC AAT GAC ATC TAC CAG GTC ACT CCT GTC 1727 232 Pro Asn Ser Tyr Val Tyr Asn Asn Asp Ile Tyr Gln Val Thr Pro Val 247 1728 TAC CGC CTC GGC TCC AAC GAC AAG GAG ATC ATG AAG GAG CTG ATG GAG 1775 248 Tyr Arg Leu Gly Ser Asn Asp Lys Glu Ile Met Lys Glu Leu Met Glu 263 1776 AAT GGC CCT GTC CAA GGT AAA CCC CCT TAT CCA GCA CCC TGG TTC CAG 1823 264 Asn Gly Pro Val Gln Gly Lys Pro Pro Tyr Pro Ala Pro Trp Phe Gln 279 1824 AAG CTT GTG CCT GCT TGA GAG TGG GCA CAG TAG CAC AAG TGG CCT GCA 1871 280 Lys Leu Val Pro Ala *** 285 1872 CAG CAT TCA GCA GCA TGT CCA GTA GGG CCA GGA GTA GGG GTC CCC CCC 1919 1920 TCC CAC AGG CAG CAC CTG GAG GGA GCA CTT AGA GCT TTG GTA TGG AGG 1967 1968 GAC CCT GGT GCC TGG GCA CAT CTC AAT AGA CTC AGG CTC CAG TGC CTG 2015 2016 TGC CAA CGG GCT GAG TGG ACC CTA CCT TGA CAT CTG CCC ACA GCC CTC 2063 2064 ATG GAG GTG CAT GAG GAC TTC TTC CTA TAC AAG GGA GGC ATC TAC AGC 2111 2112 CAC ACG CCA GTG AGC CTT GGG AGG CCA GAG AGA TAC CGC CGG CAT GGG 2159 2160 ACC CAC TCA GTC AAG ATC ACA GGA TGG GGA GAG GAG ACG CTG CCA GAT 2207 2208 GGA AGG ACG CTC AAA TAC TGG ACT GCG GCC AAC TCC TGG GGC CCA GCC 2255 2256 TGG GGC GAG AGG GGC CAC TTC CGC ATC GTG CGC GGC GTC AAT GAG TGC 2303 2304 GAC ATC GAG AGC TTC GTG CTG GGC GTC TGG GGC CGC GTG GGC ATG GAG 2351 2352 GAC ATG GGT CAT CAC TGA GGC TGC GGG CAC CAC GCG GGG TCC GGC CTG 2399 2400 GGA TCC AGG CTA AGG GCC GGC GGA AGA GGC CCC AAT GGG GCG GTG ACC 2447 2448 CCA GCC TCG CCC GAC AGA GCC CGG GGC GCA GGC GGG CGC CAG GGC GCT 2495 2496 AAT CCC GCC GCG GGT TCC GCT GAC GCA GCG CCC CGC CTG GGA GCC GCG 2543 2544 GGC AGG CGA GAC TGG CGG AGC CCC CAG ACC TCC CAG TGG GGA CGG GGC 2591 2592 AGG GCC TGG CCT GGG AAG AGC ACA GCT GCA GAT CCC AGG CCT CTG GCG 2639 2640 CCC CCA CTC AAG ACT ACC AAA GCC AGG ACA CCT CAA GTC TCC AGC CCC 2687 2688 ACT ACC CCA CCC CAC TCC TGT ATT CTT TTT TTT TTT TTT TTA GAC AGG 2735 2736 GTC TTG CTC CGT TGC CCA GGT TGG AGT GCA GTG GCC CAT CAG GGC TCA 2783 2784 CTG TAA CCT CCG ACT CCT GGG TTC AAG TGA CCC TCC CAC CTC AGC CTC 2831 2832 TCA AGT AGC TGG GAC TAC AGG TGC ACC ACC ACA CCT GGC TAA TTT TTG 2879 2880 TAT TTT TTG TAA AGA GGG GGG TCT CAC TGT GTT GCC CAG GCT GGT CTC 2927 2928 GAA CTC CTG GGC TCA AGC GGT CCA CCT GCC TCC GCC TCC CAA AGT GCT 2975 2976 GGG ATT GCA GGC ATG AGC CAC TGC ACC CAG CCC TGT ATT CTT ATT CTT 3023 3024 CAG ATA TTT ATT TTT CTT TTC ACT GTT TTA AAA TAA AAC CAA AGT ATT 3071 3072 GAT AAA AAA AAA AAA AAA AAA AAA A 3096 ...

8.PP6781

A: nucleotide sequence, (SEQ, ID, NO:22), length: 2028bp, 1, GTTGTGCCGC, TGGGGAGCCA, AACGATTGGG, AGTTGCCTCC, ACAGAGGCCC, AGAGAGGCGT, 61, CAGTTTCAAA, CTGGAAGAAA, AAACCGCCCA, CAGCAGCCTG, GCACTCTTCA, GAGATGATAC, 121, GGGTGTCAAA, TATGGCTTGG, TGGGATTGGA, GCCCACCAAG, GTGGCCTTGA, ATGTGGAGCG, 181, CTTCCGGGAG, TGGGCAGTGG, TGCTGGCAGA, CACAGCGGTC, ACCAGTGGCA, GACACTACTG, 241, GGAAGTGACA, GTGAAGCGCT, CCCAGCAGTT, TCCGATAGGA, GTGGCAGATG, TGGACATGTC, 301, CCGGGATAGC, TGCATTGGTG, TTGATGATCA, GTTCCTGGGT, GTTCACCTAT, GCCCAGCGCA, 361, AGTGGTACAC, CATGTTGGCC, AACGAGAAAG, CCCCAGTTGA, GGGTATTGGG, CAACCAGAGA, 421, AGGTGGGGCT, GTTGCTTGGA, ATATGAAGGC, CCATAAGCTG, AGCCTGGTGG, ATCGTGAAGC, 481, CAGGTCTCTG, TGAGTTCACA, CGCTACAGAC, AGATTTCCGG, GGTCCAGTGG, TGCCTGGCCT, 541, TTGCTCTCTG, GGATGGGGAG, CTGCTGACCC, ATTCAGGGCT, TGAGGTGCCC, GAGGGCCTCT, 601, AGTATGTCCA, TTACTGGAGT, CCCTAATCAC, GCCTTTGGCC, AGCCTCCTTT, TGAAAGTGTC, 661, CGAAGCCTTT, TTACTTTGCC, TCAAGCAACC, TCTAGCTCCC, ACAATTCAGT, GTTGGGTCCT, 721, CTGTGCAATA, TCATGATCAT, CTTCCTCATC, CCCTACCTTG, TGAAAGCTAG, GCATACAGCC, 781, AAACCCTCCT, TTTCCCCACC, CACCAACACT, ACTGCCAATT, TCCTAGGCTA, CCATGGGTGT, 841, ATCTTCCTTG, ACCTGCTTCC, TTCAGTCCCT, CTGCCTCCCT, TTGCCCAGGC, CTTTCTCAGA, 901, CTGTATTCCA, TCCTGGGGTC, TTATCATTCA, GCTTTGTTTG, AATTTATTTA, ATCACCATGA, 961, TACCTCTCCC, TCCCTTTGTC, CACATGTAAC, TTGTTCTTGG, GGCTCTACCA, GATGGCTGAA1021, GAGTAAATCC, TTTCTACCTC, TGGCTGAAGG, AGTGGTGCAG, TCAATGACTT, GGCCCTTTTT1081, CTACAGCACA, TTTAGAGTTT, GGGCTCTGGC, TCCCTCAGTA, AGTGCTTTAT, TAACTCAGTG1141, TGTCAAAATG, AAAACAGAGC, CCTCCTTCCC, CAGTAGCTCA, GTGCCACAGA, CCTTCAGCCC1201, CACACAGCTG, TAGCTATCCT, TACCCTGAGT, CCATCTACCT, TAAATCTGTA, CCTCTGACAC1261, CCAGCCAGTC, TGTCATAATC, ATTATCCCAG, TTATAACCTT, GACCAAAGGG, GAAGAGAGAC1321, ACTTGGGGGA, TATCTAGGGG, ATGAGTGCTA, GAAACTATTT, ATTTATTTTT, GAGACAGAGT1381, CTCACTCTGT, CACCCAGGCT, GGAGTGCAGT, GGCATGATCT, TGGCTCACTG, CAAACTCTGC1441, CTTTTGGGTT, CAAGCGACTC, TCGTGCCTCA, GCCTCCTGAG, TAGCTAGGAT, TACAGGTGTG1501, TGCCACCATG, CCCGTCTCAT, TTTTATATTT, TTAGTAGAGA, TGGGGTTTTG, CCATATTGGC1561, CAGGCTGGTC, TCGAACTCCT, GGCCTCATGT, GATCAGCCCA, CCTTGGCCTC, CCAAAGTGCT1621, GGGATTTCAG, GCGTGAGCCA, CCACACCCGG, CCAAAACTGT, TTATTCTTGA, GAAGTTCCAT1681, CTTCATTTCT, GCCACAGTTG, GAACTTCCCG, AGGAAGGAAG, GAGGCCTGAG, GTTTTGCACA1741, ATCTGTTTCA, GAGCCTGTTT, AGACTCAAAC, CTATGCTTCC, CTTGGCAGCA, GAATACACTT1801, AACCTAAAGC, AGTATTTGGA, GTTGAGAAAA, ACCTGGTGGG, GTAAGTGAAT, ATGTACTGTT1861, TGGTAGGGTA, GGTAGAGAAG, CTGTGCTTTG, ACCCTGTGAT, TCCATCTTTT, TCTACCTTCT1921, ATGATGGTGA, TGAAGCTAGA, TACCCCTAGG, GAAGAAAGAA, GGACTGGGTT, TAGCAAAAAT1981, GATTTGGTAA, TTAAAGTTTA, TTTGAACACA, AAAAAAAAAA, AAAAAAAA

B: aminoacid sequence (SEQ ID NO:23) length: 126 amino acid/11 MGVSSLTCFL QSLCLPLPRP FSDCIPSWGL IIQLCLNLFN HHDTSPSLCP HVTCSWGSTR 61 WLKSKSFLPL AEGVVQSMTW PFFYSTFRVW ALAPSVSALL TQCVKMKTEP SFPSSSVPQT121 FSPTQL

C. Nucleotide and amino acid composite sequence (SEQ ID NO:24)

Clone number: PP6781

Start code: 833 ATG stop coding: 1211 TAG

protein molecular weight: 14013.62, 1, G, TTG, TGC, CGC, TGG, GGA, GCC, AAA, CGA, TTG, GGA, GTT, GCC, TCC, ACA, GAG, 46, 47, GCC, CAG, AGA, GGC, GTC, AGT, TTC, AAA, CTG, GAA, GAA, AAA, ACC, GCC, CAC, AGC, 94, 95, AGC, CTG, GCA, CTC, TTC, AGA, GAT, GAT, ACG, GGT, GTC, AAA, TAT, GGC, TTG, GTG, 142, 143, GGA, TTG, GAG, CCC, ACC, AAG, GTG, GCC, TTG, AAT, GTG, GAG, CGC, TTC, CGG, GAG, 190, 191, TGG, GCA, GTG, GTG, CTG, GCA, GAC, ACA, GCG, GTC, ACC, AGT, GGC, AGA, CAC, TAC, 238, 239, TGG, GAA, GTG, ACA, GTG, AAG, CGC, TCC, CAG, CAG, TTT, CCG, ATA, GGA, GTG, GCA, 286, 287, GAT, GTG, GAC, ATG, TCC, CGG, GAT, AGC, TGC, ATT, GGT, GTT, GAT, GAT, CAG, TTC, 334, 335, CTG, GGT, GTT, CAC, CTA, TGC, CCA, GCG, CAA, GTG, GTA, CAC, CAT, GTT, GGC, CAA, 382, 383, CGA, GAA, AGC, CCC, AGT, TGA, GGG, TAT, TGG, GCA, ACC, AGA, GAA, GGT, GGG, GCT, 430, 431, GTT, GCT, TGG, AAT, ATG, AAG, GCC, CAT, AAG, CTG, AGC, CTG, GTG, GAT, CGT, GAA, 478, 479, GCC, AGG, TCT, CTG, TGA, GTT, CAC, ACG, CTA, CAG, ACA, GAT, TTC, CGG, GGT, CCA, 526, 527, GTG, GTG, CCT, GGC, CTT, TGC, TCT, CTG, GGA, TGG, GGA, GCT, GCT, GAC, CCA, TTC, 574, 575, AGG, GCT, TGA, GGT, GCC, CGA, GGG, CCT, CTA, GTA, TGT, CCA, TTA, CTG, GAG, TCC, 622, 623, CTA, ATC, ACG, CCT, TTG, GCC, AGC, CTC, CTT, TTG, AAA, GTG, TCC, GAA, GCC, TTT, 670, 671, TTA, CTT, TGC, CTC, AAG, CAA, CCT, CTA, GCT, CCC, ACA, ATT, CAG, TGT, TGG, GTC, 718, 719, CTC, TGT, GCA, ATA, TCA, TGA, TCA, TCT, TCC, TCA, TCC, CCT, ACC, TTG, TGA, AAG, 766, 767, CTA, GGC, ATA, CAG, CCA, AAC, CCT, CCT, TTT, CCC, CAC, CCA, CCA, ACA, CTA, CTG, 814, 815, CCA, ATT, TCC, TAG, GCT, ACC, ATG, GGT, GTA, TCT, TCC, TTG, ACC, TGC, TTC, CTT, 862, 1, Met, Gly, Val, Ser, Ser, Leu, Thr, Cys, Phe, Leu, 10, 863, CAG, TCC, CTC, TGC, CTC, CCT, TTG, CCC, AGG, CCT, TTC, TCA, GAC, TGT, ATT, CCA, 910, 11, Gln, Ser, Leu, Cys, Leu, Pro, Leu, Pro, Arg, Pro, Phe, Ser, Asp, Cys, Ile, Pro, 26, 911, TCC, TGG, GGT, CTT, ATC, ATT, CAG, CTT, TGT, TTG, AAT, TTA, TTT, AAT, CAC, CAT, 958, 27, Ser, Trp, Gly, Leu, Ile, Ile, Gln, Leu, Cys, Leu, Asn, Leu, Phe, Asn, His, His, 42, 959, GAT, ACC, TCT, CCC, TCC, CTT, TGT, CCA, CAT, GTA, ACT, TGT, TCT, TGG, GGC, TCT, 1006, 43, Asp, Thr, Ser, Pro, Ser, Leu, Cys, Pro, His, Val, Thr, Cys, Ser, Trp, Gly, Ser, 581007, ACC, AGA, TGG, CTG, AAG, AGT, AAA, TCC, TTT, CTA, CCT, CTG, GCT, GAA, GGA, GTG, 1054, 59, Thr, Arg, Trp, Leu, Lys, Ser, Lys, Ser, Phe, Leu, Pro, Leu, Ala, Glu, Gly, Val, 741055, GTG, CAG, TCA, ATG, ACT, TGG, CCC, TTT, TTC, TAC, AGC, ACA, TTT, AGA, GTT, TGG, 1102, 75, Val, Gln, Ser, Met, Thr, Trp, Pro, Phe, Phe, Tyr, Ser, Thr, Phe, Arg, Val, Trp, 901103, GCT, CTG, GCT, CCC, TCA, GTA, AGT, GCT, TTA, TTA, ACT, CAG, TGT, GTC, AAA, ATG, 1150, 91, Ala, Leu, Ala, Pro, Ser, Val, Ser, Ala, Leu, Leu, Thr, Gln, Cys, Val, Lys, Met, 1061151, AAA, ACA, GAG, CCC, TCC, TTC, CCC, AGT, AGC, TCA, GTG, CCA, CAG, ACC, TTC, AGC, 1198, 107, Lys, Thr, Glu, Pro, Ser, Phe, Pro, Ser, Ser, Ser, Val, Pro, Gln, Thr, Phe, Ser, 1221199, CCC, ACA, CAG, CTG, TAG, CTA, TCC, TTA, CCC, TGA, GTC, CAT, CTA, CCT, TAA, ATC, 1246, 123, Pro, Thr, Gln, Leu, * *, 1271247, TGT, ACC, TCT, GAC, ACC, CAG, CCA, GTC, TGT, CAT, AAT, CAT, TAT, CCC, AGT, TAT, 12941295, AAC, CTT, GAC, CAA, AGG, GGA, AGA, GAG, ACA, CTT, GGG, GGA, TAT, CTA, GGG, GAT, 13421343, GAG, TGC, TAG, AAA, CTA, TTT, ATT, TAT, TTT, TGA, GAC, AGA, GTC, TCA, CTC, TGT, 13901391, CAC, CCA, GGC, TGG, AGT, GCA, GTG, GCA, TGA, TCT, TGG, CTC, ACT, GCA, AAC, TCT, 14381439, GCC, TTT, TGG, GTT, CAA, GCG, ACT, CTC, GTG, CCT, CAG, CCT, CCT, GAG, TAG, CTA, 14861487, GGA, TTA, CAG, GTG, TGT, GCC, ACC, ATG, CCC, GTC, TCA, TTT, TTA, TAT, TTT, TAG, 15341535, TAG, AGA, TGG, GGT, TTT, GCC, ATA, TTG, GCC, AGG, CTG, GTC, TCG, AAC, TCC, TGG, 15821583, CCT, CAT, GTG, ATC, AGC, CCA, CCT, TGG, CCT, CCC, AAA, GTG, CTG, GGA, TTT, CAG, 16301631, GCG, TGA, GCC, ACC, ACA, CCC, GGC, CAA, AAC, TGT, TTA, TTC, TTG, AGA, AGT, TCC, 16781679, ATC, TTC, ATT, TCT, GCC, ACA, GTT, GGA, ACT, TCC, CGA, GGA, AGG, AAG, GAG, GCC, 17261727, TGA, GGT, TTT, GCA, CAA, TCT, GTT, TCA, GAG, CCT, GTT, TAG, ACT, CAA, ACC, TAT, 17741775, GCT, TCC, CTT, GGC, AGC, AGA, ATA, CAC, TTA, ACC, TAA, AGC, AGT, ATT, TGG, AGT, 18221823, TGA, GAA, AAA, CCT, GGT, GGG, GTA, AGT, GAA, TAT, GTA, CTG, TTT, GGT, AGG, GTA, 18701871, GGT, AGA, GAA, GCT, GTG, CTT, TGA, CCC, TGT, GAT, TCC, ATC, TTT, TTC, TAC, CTT, 19181919, CTA, TGA, TGG, TGA, TGA, AGC, TAG, ATA, CCC, CTA, GGG, AAG, AAA, GAA, GGA, CTG, 19661967, GGT, TTA, GCA, AAA, ATG, ATT, TGG, TAA, TTA, AAG, TTT, ATT, TGA, ACA, CAA, AAA, 20142015, AAA, AAA, AAA, AAA, AA, 2028

9.PP6832

A: nucleotide sequence, (SEQ, ID, NO:25), length: 1692bp, 1, GGGCCGGTCT, TGCAGAGTAG, CTGCGGTGAG, TGGGCGTGTG, CGCCGAGCGG, TCTGGCCCAA, 61, GGGCTGGGGG, CCGGCCGAGG, GTCTTCGGGA, GCAGGCCGCA, GGGCGCGGAG, AGATCCTGGG, 121, ATCGCCGTCC, GCCGCTGCTA, CCCGGCATGT, CGGCGGAGGC, CTCGGGCCCG, GCTGCGGCCG, 181, CGGCCCCGTC, CCTGGAAGCC, CCCAAGCCCT, CGGGTCTCGA, GCCTGGCCCC, GCCGCCTACG, 241, GTCTCAAGCC, GCTGACCCCG, AACAGCAAAT, ACGTGAAGCT, GAACGTGGGC, GGCTCGTTGC, 301, ACTACACCAC, GCTGCGCACC, CTCACGGGAC, AGGACACCAT, GCTCAAAGCC, ATGTTCAGCG, 361, GCCGCGTGGA, GGTGCTGACC, GATGCCGGAG, GTTGGGTGCT, GATTGACCGG, AGCGGCCGTC, 421, ACTTTGGTAC, AATCCTCAAT, TACCTGCGGG, ATGGGTCTGT, GCCACTGCCG, GAGAGTACGA, 481, GAGAACTGGG, GGAGCTGCTG, GGCGAAGCAC, GCTACTACCT, GGTGCAGGGC, CTGATTGAGG, 541, ACTGCCAGCT, GGCGCTGCAG, CAAAAAAGGG, AGACGCTGTC, CCCGCTGTGC, CTCATCCCCA, 601, TGGTGACATC, TCCCCGGGAG, GAGCAGCAGC, TCCTGGCCAG, CACCTCCAAG, CCCGTGGTGA, 661, AGCTCCTGCA, CAACCGCAGT, AACAACAAGT, ACTCCTACAC, CAGCACTTCA, GATGACAACC, 721, TACTTAAGAA, CATCGAGCTG, TTCGACAAGC, TGGCCCTGCG, CTTCCACGGG, CGGCTACTCT, 781, TCCTCAAGGA, TGTCCTGGGG, GACGAGATCT, GCTGCTGGTC, TTTCTACGGG, CAGGGCCGCA, 841, AAATCGCCGA, GGTGTGCTGC, ACCTCCATTG, TCTATGCTAC, GGAGAAGAAG, CAGACCAAGG, 901, TGGAATTTCC, AGAGGCCCGG, ATCTTCGAGG, AGACCCTGAA, CATCCTCATC, TACGAGACTC, 961, CCCGGGGCCC, AGACCCAGCC, CTCCTGGAGG, CCACAGGGGG, AGCAGCTGGA, GCTGGTGGGG1021, CTGGCCGCGG, GGAGGATGAA, GAGAACCGAG, AGCACCGTGT, CCGCAGGATC, CATGTCCGGC1081, GCCATATCAC, CCACGACGAG, CGTCCTCATG, GCCAACAAAT, TGTCTTCAAG, GACTGACCTC1141, TGACCCTCCC, CCTGCCTTCC, TCTTGCCTTG, GGACCCAGTC, CCTCTCTCTT, TCCCTCCCCT1201, TCCCAGACTT, TTGCCCCGGC, TCTGCTGGCC, AAGTCGTGGG, TCCTCCTCTG, TCCCTTCATT1261, GCATGGCACA, GCTCACTTTG, GCCCTTCTCC, ACCCATCCCA, ACCCCATTGC, TAACAACATG1321, GTACATTCCG, GCCCCACCAC, TCAGAGCCTT, CCGAAGCCAA, CACTTGTCCC, CACCCTGGCC1381, CTGCGTCCTT, CCCTCTCCAG, CTGGTTAAGA, GGGATTTAGA, ATTCCCTTTC, TCTTTTTTTA1441, GTGCATCGTC, CATGCCAAAG, TGTGCGGCCC, TTCCTGACAT, CACCACAGTC, TGAGCAGCCT1501, CCCGCGTCCT, GCAGGGTAGT, CCGCCCCCTC, CTCCCCACCA, TCCTCCCTAC, CTCCTTAACT1561, TTGTACTAGA, CTGGCCTGGG, CCTGCCCAGC, TCAGCGTTAT, CAGTCTGTTT, CATATTATTT1621, ATTATTTTAA, TTTTCTATTA, AATTATTGAA, ATAAAGTTAA, GTTGAGAAAC, TGAAAAAAAA1681, AAAAAAAAAA, AA

Protein Weight: 30892.43 1 GA TTC GCT ACC GCC TGG GCA CCA TCC GCC CAT CTT CCT CGG TCA TGA 47 48 ACA TGC ATG AAA TTT ATG TAA GTC CAT CCT TCC CCA CAA TGC TGC CAT 95 96 CTC CCC ATG GCT CAG AAC CTC AGG GAT GCT GGC CCT GTG CCC TGC TCC 143 144 TCC AAG GGC CTG GAC CAT CCC CTA CTA CAA GGC TGT GTG TCC CTG GAC 191 192 AAG TTA CTC CCC TTC TCT GGG CCT CTG TTC CCT GCT TCC ACA GGA TGT 239 240 GCT GTG CTG GAA GAA CTG ATG CTC AGA TTG AAT TTC GTG GTC TTG GCA 287 288 TCA GCT CCC CCC TGA TCT CTC CAG CCT GGG AAA AAT GCT GTT GGT CTC 335 336 AGT ACA GCT GGG TTA GGG CCC AAG GGG ACA GGG GGT CAC CTT GGT ATT 383 384 TTG GGA AGG GAA GGA CAC ACA CTC CTC CAG TTC TGG CCA GAG GGC AGC 431 432 AGT TCT CGG AAA TAA ATG CCG GTT CAG CGG AAC CCC AAG GGA GGA GAG 479 480 GGC TTC TCC CTT CCC ACC AGT GGG ACC CTC TGG GAG AGG AAT GAA AAC 527 528 CAG GCC CAA AGT GAA AGG GTG AGG AAG GGG AGC TTC AGC AGG CCT GGA 575 576 CCG GGA CAT GTG CCG GAG CAT TTG TCC ATC AGT GGC AGG CAG CGG GGA 623 624 GGC AGG GGC TGG CAG GAG TGG CCC TCC CTG CGG AGA CTT CGG CCT TGG 671 672 GTG ACC AGA CCC TGG CCC TGC CCT TAT TCC CCT GGG CCT CTG GCT ATT 719 720 TTC TGC CTC TTG CTG TTT GTG TTG GCA GAC TGC CTG GTC ACG GGA CCC 767 768 TAC TGC CTC TTC CCT CCC CTG AGG GAA AGC TAA GGC CTG AAG AAA GCT 815 816 AAG GCC GAT CAG AAG GTG CAG AGG AAA GAG GCA GGG GTT GAG AAT GGA 863 864 AAG CTG AGG GAC CTG GCC TGG CCA CTT CTC TGT GCC TGG CCT CAG CTG 911 912 CCT CAT CTG GGA AGC AGG ACT AGT CAC CAC CGC CAC CCC GCC CCG CCC 959 960 CAC CAC CTG ATA CCT GGG AGG CAC TAA ATG GTG CTT GGT TCT TCA ACA 1007 1 Met Val Leu Gly Ser Ser Thr 7 1008 CAA GTC AAA ATT GGA GGC AGC TGG AAT CCT GCA GCA GCA GGA GGG CTC 1055 8 Gln Val Lys Ile Gly Gly Ser Trp Asn Pro Ala Ala Ala Gly Gly Leu 23 1056 AAG ATT AAA CTG CAG AAG GCC CTG GAC TTG GTG GCC CTC CAG TGC CAA 1103 24 Lys Ile Lys Leu Gln Lys Ala Leu Asp Leu Val Ala Leu Gln Cys Gln 39 1104 TGG GCA CCT GAG GGG CAG GCC AGG GCA GAG CAG GAG GCA GAC AGG GCA 1151 40 Trp Ala Pro Glu Gly Gln Ala Arg Ala Glu Gln Glu Ala Asp Arg Ala 55 1152 ACC TTT ATC TTG CAG ACA GTG CTG AAC CCA GGG GAG GTG CTT CCC ACA 1199 56 Thr Phe Ile Leu Gln Thr Val Leu Asn Pro Gly Glu Val Leu Pro Thr 71 1200 GCC TTC GAG GCC TCT GAG AAG TGG CCC AAC CTG ATT CAT GAG CCT CTT 1247 72 Ala Phe Glu Ala Ser Glu Lys Trp Pro Asn Leu Ile His Glu Pro Leu 87 1248 GAC CAA GGC AAC TGT GCA GGC TCC TGG GCC TTC TCC ACA GCA GCT GTG 1295 88 Asp Gln Gly Asn Cys Ala Gly Ser Trp Ala Phe Ser Thr Ala Ala Val 103 1296 GCA TCC GAT CGT GTC TCA ATC CAT TCT CTG GGA CAC ATG ACG CCT GTC 1343 104 Ala Ser Asp Arg Val Ser Ile His Ser Leu Gly His Met Thr Pro Val 119 1344 CTG TCG CCC CAG AAC CTG CTG TCT TGT GAC ACC CAC CAG CAG CAG GGC 1391 120 Leu Ser Pro Gln Asn Leu Leu Ser Cys Asp Thr His Gln Gln Gln Gly 135 1392 TGC CGC GGT GGG CGT CTC GAT GGT GCC TGG TGG TTC CTG CGT CGC CGA 1439 136 Cys Arg Gly Gly Arg Leu Asp Gly Ala Trp Trp Phe Leu Arg Arg Arg 151 1440 GGG TAT GCA GCA ACA GGG GAT GTG GGC AGA GAA GAG GGC AAG GAG CTC 1487 152 Gly Tyr Ala Ala Thr Gly Asp Val Gly Arg Glu Glu Gly Lys Glu Leu 167 1488 CGT GGG CAT GGC CTG GGC CAT GAT GCA CTG AGT CTT TCT GCC TTT GCT 1535 168 Arg Gly His Gly Leu Gly His Asp Ala Leu Ser Leu Ser Ala Phe Ala 183 1536 CCC TCT TGC TGC CTT TGC AGG GTG GTG TCT GAC CAC TGC TAC CCC TTC 1583 184 Pro Ser Cys Cys Leu Cys Arg Val Val Ser Asp His Cys Tyr Pro Phe 199 1584 TCG GGC CGT GAA CGA GAC GAG GCT GGC CCT GCG CCC CCC TGT ATG ATG 1631 200 Ser Gly Arg Glu Arg Asp Glu Ala Gly Pro Ala Pro Pro Cys Met Met 215 1632 CAC AGC CGA GCC ATG GGT CGG GGC AAG CGC CAG GCC ACT GCC CAC TGC 1679 216 His Ser Arg Ala Met Gly Arg Gly Lys Arg Gln Ala Thr Ala His Cys 231 1680 CCC AAC AGC TAT GTT TAT AAC AAT GAC ATC TAC CAG GTC ACT CCT GTC 1727 232 Pro Asn Ser Tyr Val Tyr Asn Asn Asp Ile Tyr Gln Val Thr Pro Val 247 1728 TAC CGC CTC GGC TCC AAC GAC AAG GAG ATC ATG AAG GAG CTG ATG GAG 1775 248 Tyr Arg Leu Gly Ser Asn Asp Lys Glu Ile Met Lys Glu Leu Met Glu 263 1776 AAT GGC CCT GTC CAA GGT AAA CCC CCT TAT CCA GCA CCC TGG TTC CAG 1823 264 Asn Gly Pro Val Gln Gly Lys Pro Pro Tyr Pro Ala Pro Trp Phe Gln 279 1824 AAG CTT GTG CCT GCT TGA GAG TGG GCA CAG TAG CAC AAG TGG CCT GCA 1871 280 Lys Leu Val Pro Ala *** 285 1872 CAG CAT TCA GCA GCA TGT CCA GTA GGG CCA GGA GTA GGG GTC CCC CCC 1919 1920 TCC CAC AGG CAG CAC CTG GAG GGA GCA CTT AGA GCT TTG GTA TGG AGG 1967 1968 GAC CCT GGT GCC TGG GCA CAT CTC AAT AGA CTC AGG CTC CAG TGC CTG 2015 2016 TGC CAA CGG GCT GAG TGG ACC CTA CCT TGA CAT CTG CCC ACA GCC CTC 2063 2064 ATG GAG GTG CAT GAG GAC TTC TTC CTA TAC AAG GGA GGC ATC TAC AGC 2111 2112 CAC ACG CCA GTG AGC CTT GGG AGG CCA GAG AGA TAC CGC CGG CAT GGG 2159 2160 ACC CAC TCA GTC AAG ATC ACA GGA TGG GGA GAG GAG ACG CTG CCA GAT 2207 2208 GGA AGG ACG CTC AAA TAC TGG ACT GCG GCC AAC TCC TGG GGC CCA GCC 2255 2256 TGG GGC GAG AGG GGC CAC TTC CGC ATC GTG CGC GGC GTC AAT GAG TGC 2303 2304 GAC ATC GAG AGC TTC GTG CTG GGC GTC TGG GGC CGC GTG GGC ATG GAG 2351 2352 GAC ATG GGT CAT CAC TGA GGC TGC GGG CAC CAC GCG GGG TCC GGC CTG 2399 2400 GGA TCC AGG CTA AGG GCC GGC GGA AGA GGC CCC AAT GGG GCG GTG ACC 2447 2448 CCA GCC TCG CCC GAC AGA GCC CGG GGC GCA GGC GGG CGC CAG GGC GCT 2495 2496 AAT CCC GCC GCG GGT TCC GCT GAC GCA GCG CCC CGC CTG GGA GCC GCG 2543 2544 GGC AGG CGA GAC TGG CGG AGC CCC CAG ACC TCC CAG TGG GGA CGG GGC 2591 2592 AGG GCC TGG CCT GGG AAG AGC ACA GCT GCA GAT CCC AGG CCT CTG GCG 2639 2640 CCC CCA CTC AAG ACT ACC AAA GCC AGG ACA CCT CAA GTC TCC AGC CCC 2687 2688 ACT ACC CCA CCC CAC TCC TGT ATT CTT TTT TTT TTT TTT TTA GAC AGG 2735 2736 GTC TTG CTC CGT TGC CCA GGT TGG AGT GCA GTG GCC CAT CAG GGC TCA 2783 2784 CTG TAA CCT CCG ACT CCT GGG TTC AAG TGA CCC TCC CAC CTC AGC CTC 2831 2832 TCA AGT AGC TGG GAC TAC AGG TGC ACC ACC ACA CCT GGC TAA TTT TTG 2879 2880 TAT TTT TTG TAA AGA GGG GGG TCT CAC TGT GTT GCC CAG GCT GGT CTC 2927 2928 GAA CTC CTG GGC TCA AGC GGT CCA CCT GCC TCC GCC TCC CAA AGT GCT 2975 2976 GGG ATT GCA GGC ATG AGC CAC TGC ACC CAG CCC TGT ATT CTT ATT CTT 3023 3024 CAG ATA TTT ATT TTT CTT TTC ACT GTT TTA AAA TAA AAC CAA AGT ATT 3071 3072 GAT AAA AAA AAA AAA AAA AAA AAA A 3096 ...

C. Nucleotide and amino acid composite sequence (SEQ ID NO:27)

Clone number: PP6832

Start code: 147 ATG stop coding: 1134 TGA

protein molecular weight: 36355.48, 1, GG, GCC, GGT, CTT, GCA, GAG, TAG, CTG, CGG, TGA, GTG, GGC, GTG, TGC, GCC, GAG, 47, 48, CGG, TCT, GGC, CCA, AGG, GCT, GGG, GGC, CGG, CCG, AGG, GTC, TTC, GGG, AGC, AGG, 95, 96, CCG, CAG, GGC, GCG, GAG, AGA, TCC, TGG, GAT, CGC, CGT, CCG, CCG, CTG, CTA, CCC, 143144, GGC, ATG, TCG, GCG, GAG, GCC, TCG, GGC, CCG, GCT, GCC, GCC, GCG, GCC, CCG, TCC, 191, 1, Met, Ser, Ala, Glu, Ala, Ser, Gly, Pro, Ala, Ala, Ala, Ala, Ala, Pro, Ser, 15192, CTG, GAA, GCC, CCC, AAG, CCC, TCG, GGT, CTC, GAG, CCT, GGC, CCC, GCC, GCC, TAC, 239, 16, Leu, Glu, Ala, Pro, Lys, Pro, Ser, Gly, Leu, Glu, Pro, Gly, Pro, Ala, Ala, Tyr, 31240, GGT, CTC, AAG, CCG, CTG, ACC, CCG, AAC, AGC, AAA, TAC, GTG, AAG, CTG, AAC, GTG, 287, 32, Gly, Leu, Lys, Pro, Leu, Thr, Pro, Asn, Ser, Lys, Tyr, Val, Lys, Leu, Asn, Val, 47288, GGC, GGC, TCG, TTG, CAC, TAC, ACC, ACG, CTG, CGC, ACC, CTC, ACG, GGA, CAG, GAC, 335, 48, Gly, Gly, Ser, Leu, His, Tyr, Thr, Thr, Leu, Arg, Thr, Leu, Thr, Gly, Gln, Asp, 63336, ACC, ATG, CTC, AAA, GCC, ATG, TTC, AGC, GGC, CGC, GTG, GAG, GTG, CTG, ACC, GAT, 383, 64, Thr, Met, Leu, Lys, Ala, Met, Phe, Ser, Gly, Arg, Val, Glu, Val, Leu, Thr, Asp, 79384, GCC, GGA, GGT, TGG, GTG, CTG, ATT, GAC, CGG, AGC, GGC, CGT, CAC, TTT, GGT, ACA, 431, 80, Ala, Gly, Gly, Trp, Val, Leu, Ile, Asp, Arg, Ser, Gly, Arg, His, Phe, Gly, Thr, 95432, ATC, CTC, AAT, TAC, CTG, CGG, GAT, GGG, TCT, GTG, CCA, CTG, CCG, GAG, AGT, ACG, 47996, Ile, Leu, Asn, Tyr, Leu, Arg, Asp, Gly, Ser, Val, Pro, Leu, Pro, Glu, Ser, Thr, 111480, AGA, GAA, CTG, GGG, GAG, CTG, CTG, GGC, GAA, GCA, CGC, TAC, TAC, CTG, GTG, CAG, 527112, Arg, Glu, Leu, Gly, Glu, Leu, Leu, Gly, Glu, Ala, Arg, Tyr, Tyr, Leu, Val, Gln, 127528, GGC, CTG, ATT, GAG, GAC, TGC, CAG, CTG, GCG, CTG, CAG, CAA, AAA, AGG, GAG, ACG, 575128, Gly, Leu, Ile, Glu, Asp, Cys, Gln, Leu, Ala, Leu, Gln, Gln, Lys, Arg, Glu, Thr, 143576, CTG, TCC, CCG, CTG, TGC, CTC, ATC, CCC, ATG, GTG, ACA, TCT, CCC, CGG, GAG, GAG, 623144, Leu, Ser, Pro, Leu, Cys, Leu, Ile, Pro, Met, Val, Thr, Ser, Pro, Arg, Glu, Glu, 159624, CAG, CAG, CTC, CTG, GCC, AGC, ACC, TCC, AAG, CCC, GTG, GTG, AAG, CTC, CTG, CAC, 671160, Gln, Gln, Leu, Leu, Ala, Ser, Thr, Ser, Lys, Pro, Val, Val, Lys, Leu, Leu, His, 175672, AAC, CGC, AGT, AAC, AAC, AAG, TAC, TCC, TAC, ACC, AGC, ACT, TCA, GAT, GAC, AAC, 719176, Asn, Arg, Ser, Asn, Asn, Lys, Tyr, Ser, Tyr, Thr, Ser, Thr, Ser, Asp, Asp, Asn, 191, 720, CTA, CTT, AAG, AAC, ATC, GAG, CTG, TTC, GAC, AAG, CTG, GCC, CTG, CGC, TTC, CAC, 767, 192, Leu, Leu, Lys, Asn, Ile, Glu, Leu, Phe, Asp, Lys, Leu, Ala, Leu, Arg, Phe, His, 207, 768, GGG, CGG, CTA, CTC, TTC, CTC, AAG, GAT, GTC, CTG, GGG, GAC, GAG, ATC, TGC, TGC, 815, 208, Gly, Arg, Leu, Leu, Phe, Leu, Lys, Asp, Val, Leu, Gly, Asp, Glu, Ile, Cys, Cys, 223, 816, TGG, TCT, TTC, TAC, GGG, CAG, GGC, CGC, AAA, ATC, GCC, GAG, GTG, TGC, TGC, ACC, 863, 224, Trp, Ser, Phe, Tyr, Gly, Gln, Gly, Arg, Lys, Ile, Ala, Glu, Val, Cys, Cys, Thr, 239, 864, TCC, ATT, GTC, TAT, GCT, ACG, GAG, AAG, AAG, CAG, ACC, AAG, GTG, GAA, TTT, CCA, 911, 240, Ser, Ile, Val, Tyr, Ala, Thr, Glu, Lys, Lys, Gln, Thr, Lys, Val, Glu, Phe, Pro, 255, 912, GAG, GCC, CGG, ATC, TTC, GAG, GAG, ACC, CTG, AAC, ATC, CTC, ATC, TAC, GAG, ACT, 959, 256, Glu, Ala, Arg, Ile, Phe, Glu, Glu, Thr, Leu, Asn, Ile, Leu, Ile, Tyr, Glu, Thr, 271, 960, CCC, CGG, GGC, CCA, GAC, CCA, GCC, CTC, CTG, GAG, GCC, ACA, GGG, GGA, GCA, GCT, 1007, 272, Pro, Arg, Gly, Pro, Asp, Pro, Ala, Leu, Leu, Glu, Ala, Thr, Gly, Gly, Ala, Ala, 2871008, GGA, GCT, GGT, GGG, GCT, GGC, CGC, GGG, GAG, GAT, GAA, GAG, AAC, CGA, GAG, CAC, 1055, 288, Gly, Ala, Gly, Gly, Ala, Gly, Arg, Gly, Glu, Asp, Glu, Glu, Asn, Arg, Glu, His, 3031056, CGT, GTC, CGC, AGG, ATC, CAT, GTC, CGG, CGC, CAT, ATC, ACC, CAC, GAC, GAG, CGT, 1103, 304, Arg, Val, Arg, Arg, Ile, His, Val, Arg, Arg, His, Ile, Thr, His, Asp, Glu, Arg, 3191104, CCT, CAT, GGC, CAA, CAA, ATT, GTC, TTC, AAG, GAC, TGA, CCT, CTG, ACC, CTC, CCC, 1151, 320, Pro, His, Gly, Gln, Gln, Ile, Val, Phe, Lys, Asp, * *, 3301152, CTG, CCT, TCC, TCT, TGC, CTT, GGG, ACC, CAG, TCC, CTC, TCT, CTT, TCC, CTC, CCC, 11991200, TTC, CCA, GAC, TTT, TGC, CCC, GGC, TCT, GCT, GGC, CAA, GTC, GTG, GGT, CCT, CCT, 12471248, CTG, TCC, CTT, CAT, TGC, ATG, GCA, CAG, CTC, ACT, TTG, GCC, CTT, CTC, CAC, CCA, 12951296, TCC, CAA, CCC, CAT, TGC, TAA, CAA, CAT, GGT, ACA, TTC, CGG, CCC, CAC, CAC, TCA, 13431344, GAG, CCT, TCC, GAA, GCC, AAC, ACT, TGT, CCC, CAC, CCT, GGC, CCT, GCG, TCC, TTC, 13911392, CCT, CTC, CAG, CTG, GTT, AAG, AGG, GAT, TTA, GAA, TTC, CCT, TTC, TCT, TTT, TTT, 14391440, AGT, GCA, TCG, TCC, ATG, CCA, AAG, TGT, GCG, GCC, CTT, CCT, GAC, ATC, ACC, ACA, 14871488, GTC, TGA, GCA, GCC, TCC, CGC, GTC, CTG, CAG, GGT, AGT, CCG, CCC, CCT, CCT, CCC, 15351536, CAC, CAT, CCT, CCC, TAC, CTC, CTT, AAC, TTT, GTA, CTA, GAC, TGG, CCT, GGG, CCT, 15831584, GCC, CAG, CTC, AGC, GTT, ATC, AGT, CTG, TTT, CAT, ATT, ATT, TAT, TAT, TTT, AAT, 16311632, TTT, CTA, TTA, AAT, TAT, TGA, AAT, AAA, GTT, AAG, TTG, AGA, AAC, TGA, AAA, AAA, 16791680, AAA, AAA, AAA, AAA, A, 1692

10.PP6933

A: nucleotide sequence, (SEQ, ID, NO:28), length: 1649bp, 1, GCTGGAGGAG, CCGGGCCGAG, GCCGCGGCGG, AGGCCGCGGC, TGGTACTGGG, AGGGTGGCAG, 61, GGAGGGACGG, GGAAGGAAGA, TGGCGACGTC, GGGGGCGAAC, GGGCCTGGTT, CGGCCACGGC121, CTCGGCTTCC, AATCCGCGCA, AATTTAGTGA, GAAGATTGCG, CTGCAGAAGC, AGCGTCAGGC181, TTCCCTGAGC, AGTCCTCAGC, CCCAGCTTCA, GGGCTCCCAC, AGCCACCCCT, CTCTGCCTGC241, CTCCTCCTTG, GCCCGCCATG, TACTGCCCAC, CACCTCCCTG, GGCCACCCCT, CACTCAGTGC301, TCCGGCTCTC, TCCTCCTCCT, CTTCCTCCTC, CTCCACTTCA, TCTCCTGTTT, TGGGCGCCCC361, CTCTTACCCT, GCTTCTACCC, CTGGGGCTCC, CCCCACCACC, GCCGTGTGCC, CCTCAGCCCC421, CTGAGTTTGC, TCGCGGGCCC, AGCCGACGCC, AGAAGGTCCC, AACAGCAGCT, GCCCAAACAG, 481, TTTTCGCCAA, CAATGTCACC, CACCTTGTCT, TCCATCACTC, AGGGCGTCCC, CCTGGATACC, 541, AGTAAACTGT, CCACTGACCA, GCGGTTACCC, CCATACCCAT, ACAGCTCCCC, AAGTCTGGTT, 601, CTGCCTACCC, AGCCCCACAC, CCCAAAGTCT, CTACAGCAGC, CAGGGCTGCC, CTCTCAGTCT, 661, TGTTCAGTGC, AGTCCTCAGG, TGGGCAGCCC, CCAGGCAGGC, AGTCTCATTA, TGGGACACCG, 721, TACCCACCTG, GGCCCAGTGG, GCATGGGCAA, CAGTCTTACC, ACCGGCCAAT, GAGTGACTTC, 781, AACCTGGGGA, ATCTGGAGCA, GTTCAGCATG, GAGAGCCCAT, CAGCCAGCCT, GGTGCTGGAT, 841, CCCCCTGGCT, TTTCTGAAGG, GCCTGGATTT, TTAGGGGGTG, AGGGGCCAAT, GGGTGGCCCC, 901, CAGGATCCCC, ACACCTTCAA, CCACCAGAAC, TTGACCCACT, GTTCCCGCCA, TGGCTCAGGG, 961, CCTAACATCA, TCCTCACAGG, GGACTCCTCT, CCAGGTTTCT, CTAAGGAGAT, TGCAGCAGCC1021, CTGGCCGGAG, TGGCTGGCTT, TGAGGTGTCA, GCAGCTGGAT, TGGAGCTAGG, GCTTGGGCTA1081, GAAGATGAGC, TGCGCATGGA, GCCACTGGGC, CTGGAAGGGC, TAAACATGCT, GAGTGACCCC1141, TGTGCCCTGC, TGCCTGATCC, TGCTGTGGAG, GAGTCATTCC, GCAGTGACCG, GCTCCAATGA1201, GGGCACCTCA, TCACCATCCC, TCTTCTTGGC, CCCATCCCCC, ACCACCATTC, CTTTCCTCCC1261, TTCCCCCTGG, CAGGTAGAGA, CTCTACTCTC, TGTCCCCAGA, TCCTCTTTCT, AGCATGAATG1321, AAGGATGCCA, AGAATGAGAA, AAAGCAAGGG, GTTTGTCCAG, GTGGCCCCTG, AATTCTGCGC1381, AAGGGATGGG, CCTGGGGGAA, CTCAAGGGAG, GGCCTAAAGC, ACTTGTAACT, TTGAACCGTC1441, TGTCTGGAGG, TCAGAGCCTG, TTGGAAAGCA, GGGGTAGAGG, GGAGCCCTGG, AAGCAGGGCT1501, TTTCCGGATG, CCTAGGGGTG, GGCAGTGCCA, GCCCCTCCTC, ACCACTCTTC, CCCTTGCAGT1561, GGAGGAGAGA, GCCAGAGTGG, ATACTATTTT, TTATTAAATA, TATTATTATA, TGTTAATAAA1621, AAAATCATAT, CAAAAAAAAA, AAAAAAAAA

B: amino acid sequence (SEQ ID NO:29) length: 235 amino acid/11 MSPTLSSITQ GVPLDTSKLS TDQRLPPYPY SSPSLVLPTQ PHTPKSLQQP GLPSQSCSVQ 61 SSGGQPPGRQ SHYGTPYPPG PSGHGQQSYH RPMSDFNLGN LEQFSMESPS ASLVLDPPGF121 SEGPGFLGGE GPMGGPQDPH TFNHQNLTHC SRHGSGPNII LTGDSSPGFS KEIAAALAGV181 PGFEVSAAGL ELGLGLEDEL RMEPLGLEGL NMLSDPCALL PDPAVEESFR SDRLQ

C. Nucleotide and amino acid composite sequence (SEQ ID NO:30)

Clone number: PP6933

Start code: 493 ATG stop coding: 1198 TGA

protein molecular weight: 24632.01, 1, GCT, GGA, GGA, GCC, GGG, CCG, AGG, CCG, CGG, CGG, AGG, CCG, CGG, CTG, GTA, CTG, 48, 49, GGA, GGG, TGG, CAG, GGA, GGG, ACG, GGG, AAG, GAA, GAT, GGC, GAC, GTC, GGG, GGC, 96, 97, GAA, CGG, GCC, TGG, TTC, GGC, CAC, GGC, CTC, GGC, TTC, CAA, TCC, GCG, CAA, ATT, 144145, TAG, TGA, GAA, GAT, TGC, GCT, GCA, GAA, GCA, GCG, TCA, GGC, TTC, CCT, GAG, CAG, 192193, TCC, TCA, GCC, CCA, GCT, TCA, GGG, CTC, CCA, CAG, CCA, CCC, CTC, TCT, GCC, TGC, 240241, CTC, CTC, CTT, GGC, CCG, CCA, TGT, ACT, GCC, CAC, CAC, CTC, CCT, GGG, CCA, CCC, 288289, CTC, ACT, CAG, TGC, TCC, GGC, TCT, CTC, CTC, CTC, CTC, TTC, CTC, CTC, CTC, CAC, 336337, TTC, ATC, TCC, TGT, TTT, GGG, CGC, CCC, CTC, TTA, CCC, TGC, TTC, TAC, CCC, TGG, 384385, GGC, TCC, CCC, CAC, CAC, CGC, CGT, GTG, CCC, CTC, AGC, CCC, CTG, AGT, TTG, CTC, 432433, GCG, GGC, CCA, GCC, GAC, GCC, AGA, AGG, TCC, CAA, CAG, CAG, CTG, CCC, AAA, CAG, 480481, TTT, TCG, CCA, ACA, ATG, TCA, CCC, ACC, TTG, TCT, TCC, ATC, ACT, CAG, GGC, GTC, 528, 1, Met, Ser, Pro, Thr, Leu, Ser, Ser, Ile, Thr, Gln, Gly, Val, 12529, CCC, CTG, GAT, ACC, AGT, AAA, CTG, TCC, ACT, GAC, CAG, CGG, TTA, CCC, CCA, TAC, 576, 13, Pro, Leu, Asp, Thr, Ser, Lys, Leu, Ser, Thr, Asp, Gln, Arg, Leu, Pro, Pro, Tyr, 28577, CCA, TAC, AGC, TCC, CCA, AGT, CTG, GTT, CTG, CCT, ACC, CAG, CCC, CAC, ACC, CCA, 624, 29, Pro, Tyr, Ser, Ser, Pro, Ser, Leu, Val, Leu, Pro, Thr, Gln, Pro, His, Thr, Pro, 44, 625, AAG, TCT, CTA, CAG, CAG, CCA, GGG, CTG, CCC, TCT, CAG, TCT, TGT, TCA, GTG, CAG, 672, 45, Lys, Ser, Leu, Gln, Gln, Pro, Gly, Leu, Pro, Ser, Gln, Ser, Cys, Ser, Val, Gln, 60, 673, TCC, TCA, GGT, GGG, CAG, CCC, CCA, GGC, AGG, CAG, TCT, CAT, TAT, GGG, ACA, CCG, 720, 61, Ser, Ser, Gly, Gly, Gln, Pro, Pro, Gly, Arg, Gln, Ser, His, Tyr, Gly, Thr, Pro, 76, 721, TAC, CCA, CCT, GGG, CCC, AGT, GGG, CAT, GGG, CAA, CAG, TCT, TAC, CAC, CGG, CCA, 768, 77, Tyr, Pro, Pro, Gly, Pro, Ser, Gly, His, Gly, Gln, Gln, Ser, Tyr, His, Arg, Pro, 92, 769, ATG, AGT, GAC, TTC, AAC, CTG, GGG, AAT, CTG, GAG, CAG, TTC, AGC, ATG, GAG, AGC, 816, 93, Met, Ser, Asp, Phe, Asn, Leu, Gly, Asn, Leu, Glu, Gln, Phe, Ser, Met, Glu, Ser, 108, 817, CCA, TCA, GCC, AGC, CTG, GTG, CTG, GAT, CCC, CCT, GGC, TTT, TCT, GAA, GGG, CCT, 864, 109, Pro, Ser, Ala, Ser, Leu, Val, Leu, Asp, Pro, Pro, Gly, Phe, Ser, Glu, Gly, Pro, 124, 865, GGA, TTT, TTA, GGG, GGT, GAG, GGG, CCA, ATG, GGT, GGC, CCC, CAG, GAT, CCC, CAC, 912, 125, Gly, Phe, Leu, Gly, Gly, Glu, Gly, Pro, Met, Gly, Gly, Pro, Gln, Asp, Pro, His, 140, 913, ACC, TTC, AAC, CAC, CAG, AAC, TTG, ACC, CAC, TGT, TCC, CGC, CAT, GGC, TCA, GGG, 960, 141, Thr, Phe, Asn, His, Gln, Asn, Leu, Thr, His, Cys, Ser, Arg, His, Gly, Ser, Gly, 156, 961, CCT, AAC, ATC, ATC, CTC, ACA, GGG, GAC, TCC, TCT, CCA, GGT, TTC, TCT, AAG, GAG, 1008, 157, Pro, Asn, Ile, Ile, Leu, Thr, Gly, Asp, Ser, Ser, Pro, Gly, Phe, Ser, Lys, Glu, 1721009, ATT, GCA, GCA, GCC, CTG, GCC, GGA, GTG, CCT, GGC, TTT, GAG, GTG, TCA, GCA, GCT, 1056, 173, Ile, Ala, Ala, Ala, Leu, Ala, Gly, Val, Pro, Gly, Phe, Glu, Val, Ser, Ala, Ala, 1881057, GGA, TTG, GAG, CTA, GGG, CTT, GGG, CTA, GAA, GAT, GAG, CTG, CGC, ATG, GAG, CCA, 1104, 189, Gly, Leu, Glu, Leu, Gly, Leu, Gly, Leu, Glu, Asp, Glu, Leu, Arg, Met, Glu, Pro, 2041105, CTG, GGC, CTG, GAA, GGG, CTA, AAC, ATG, CTG, AGT, GAC, CCC, TGT, GCC, CTG, CTG, 1152, 205, Leu, Gly, Leu, Glu, Gly, Leu, Asn, Met, Leu, Ser, Asp, Pro, Cys, Ala, Leu, Leu, 2201153, CCT, GAT, CCT, GCT, GTG, GAG, GAG, TCA, TTC, CGC, AGT, GAC, CGG, CTC, CAA, TGA, 1200, 221, Pro, Asp, Pro, Ala, Val, Glu, Glu, Ser, Phe, Arg, Ser, Asp, Arg, Leu, Gln, * *, 2361201, GGG, CAC, CTC, ATC, ACC, ATC, CCT, CTT, CTT, GGC, CCC, ATC, CCC, CAC, CAC, CAT, 12481249, TCC, TTT, CCT, CCC, TTC, CCC, CTG, GCA, GGT, AGA, GAC, TCT, ACT, CTC, TGT, CCC, 12961297, CAG, ATC, CTC, TTT, CTA, GCA, TGA, ATG, AAG, GAT, GCC, AAG, AAT, GAG, AAA, AAG, 13441345, CAA, GGG, GTT, TGT, CCA, GGT, GGC, CCC, TGA, ATT, CTG, CGC, AAG, GGA, TGG, GCC, 13921393, TGG, GGG, AAC, TCA, AGG, GAG, GGC, CTA, AAG, CAC, TTG, TAA, CTT, TGA, ACC, GTC, 14401441, TGT, CTG, GAG, GTC, AGA, GCC, TGT, TGG, AAA, GCA, GGG, GTA, GAG, GGG, AGC, CCT, 14881489, GGA, AGC, AGG, GCT, TTT, CCG, GAT, GCC, TAG, GGG, TGG, GCA, GTG, CCA, GCC, CCT, 15361537, CCT, CAC, CAC, TCT, TCC, CCT, TGC, AGT, GGA, GGA, GAG, AGC, CAG, AGT, GGA, TAC, 15841585, TAT, TTT, TTA, TTA, AAT, ATA, TTA, TTA, TAT, GTT, AAT, AAA, AAA, ATC, ATA, TCA, 16321633, AAA, AAA, AAA, AAA, AAA, AA, 1649

All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.

Claims (10)

1. isolating people's albumen with cancer suppressing function, it is characterized in that it comprises the polypeptide of the aminoacid sequence with the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29;

Or its conservative property variation polypeptide or its active fragments or its reactive derivative.

2. polypeptide as claimed in claim 1, it is characterized in that this polypeptide is the polypeptide with aminoacid sequence of the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ IDNO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29.

3. isolating polynucleotide is characterized in that, it comprises a nucleotide sequence, and this nucleotide sequence is shown at least 85% homogeny with a kind of nucleotides sequence that is selected from down group:

(a) coding is as the polynucleotide of polypeptide as described in claim 1 and 2;

(b) with polynucleotide (a) complementary polynucleotide.

4. polynucleotide as claimed in claim 3, it is characterized in that the polypeptide of this polynucleotide encoding has the aminoacid sequence of the group of being selected from down: SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29.

5. polynucleotide as claimed in claim 3 is characterized in that, the sequence of these polynucleotide is selected from down group:

Coding region sequence or the full length sequence of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30.

6. a carrier is characterized in that, it contains the described polynucleotide of claim 3.

7. a genetically engineered host cell is characterized in that, it is a kind of host cell that is selected from down group:

(a) host cell that transforms or transduce with the described carrier of claim 6;

(b) host cell that transforms or transduce with the described polynucleotide of claim 3.

8. the preparation method of the polypeptide of the people's protein-active with cancer suppressing function is characterized in that this method comprises:

(a) have under the proteic condition of people of cancer suppressing function suitable the expression, cultivate the described host cell of claim 7;

(b) from culture, isolate the polypeptide of people's protein-active with cancer suppressing function.

9. energy and the described people's protein-specific bonded antibody of claim 1 with cancer suppressing function.

10. a pharmaceutical composition is characterized in that, it contains the described polypeptide of claim 1 and the pharmaceutically acceptable carrier of safe and effective amount.